

Wetenschappelijk jaaroverzicht 2017

Wetenschappelijk jaaroverzicht 2017

Auteur
A.M. Kuijpers-Ruurs

Inhoudsopgave

1	Algemeen	6
1.1	Publicaties met impactfactor	6
1.2	Overige publicaties	11
1.3	Boeken en boekbijdragen	11
1.4	Posters	11
1.5	Presentaties en abstracts	11
2	Borstkanker	13
2.1	Publicaties met impactfactor	13
2.2	Overige publicaties	16
2.3	Boeken en boekbijdragen	16
2.4	Posters	16
2.5	Presentaties en abstracts	16
3	Bot-en wekedelentumoren	19
3.1	Publicaties met impactfactor	19
4	Darmkanker	20
4.1	Publicaties met impactfactor	20
4.2	Overige publicaties	22
4.3	Posters	22
4.4	Presentaties en abstracts	22
4.5	Proefschriften en promoties	23
5	Gynaecologische tumoren	24
5.1	Publicaties met impactfactor	24
5.2	Posters	26
5.3	Presentaties en abstracts	26
6	Hemato-oncologie	28
6.1	Publicaties met impactfactor	28
6.2	Overige publicaties	29
6.3	Posters	29
6.4	Presentaties en abstracts	30
7	Hoofdhalskanker	31
7.1	Publicaties met impactfactor	31
8	Huidkanker	32
8.1	Publicaties met impactfactor	32
8.2	Overige publicaties	33
8.3	Presentaties en abstracts	33
9	Longkanker	34
9.1	Publicaties met impactfactor	34
9.2	Posters	35
9.3	Presentaties en abstracts	35
10	Neuro-endocriene tumoren	36
10.1	Publicaties met impactfactor	36
11	Neuro-oncologie	37
11.1	Publicaties met impactfactor	37
12	Upper GI & HPB	38
12.1	Publicaties met impactfactor	37
12.2	Posters	40
12.3	Presentaties en abstracts	40
12.4	Proefschriften en promoties	40

13	Urogenitale kanker	41
	13.1 Publicaties met impactfactor	41
	13.2 Overige publicaties	41
	13.3 Posters	41
	13.4 Presentaties en abstracts	42
B1	Impactfactoren tijdschriften	43

1 Algemeen

1.1 Publicaties met impactfactor

Beijer S, Vogel J, Jager-Wittenaar H. Alternative terminology for the confusing term "palliative nutrition". *Clin Nutr*. 2017 Dec;36(6):1723-1724. doi: 10.1016/j.clnu.2017.09.012. Epub 2017 Sep 23. No abstract available.
Impactfactor: 4,548

de Barros Silva G, Donati A, **van den Hurk CJ**. Comments regarding "Hair regrowth during chemotherapy after scalp cooling technique". *Int J Dermatol*. 2017 Mar;56(3):e57-e59. doi: 10.1111/ijd.13526. Epub 2017 Jan 12. No abstract available. No abstract available.
Impactfactor: 1,560

de Groot S, van der Linden N, Franken MG, **Blommestein HM**, Leeneman B, van Rooijen E, Koos van der Hoeven JJ, Wouters MW, Westgeest HM, **Uyl-de Groot CA**. Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences. *Value Health*. 2017 Apr;20(4):627-636. doi: 10.1016/j.jval.2016.02.007. Epub 2016 Apr 6.
Impactfactor: 4,235

Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, Comber H, Dimitrova N, Leinonen MK, **Siesling S, van der Zwan JM**, Van Eycken L, **Visser O**, Žakelj MP, Anderson LA, Bella F, Kaire I, Otter R, Stiller CA, Trama A; RARECAREnet working group. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. *Lancet Oncol*. 2017 Aug;18(8):1022-1039. doi: 10.1016/S1470-2045(17)30445-X. Epub 2017 Jul 4.
Impactfactor: 33,900

Gatta G, Trama A, Capocaccia R; RARECARENet Working Group (**Visser O**). Epidemiology of rare cancers and inequalities in oncologic outcomes. *Eur J Surg Oncol*. 2017 Sep 19. pii: S0748-7983(17)30685-6. doi: 10.1016/j.ejso.2017.08.018. [Epub ahead of print]
Impactfactor: 3,522

Huibertse LJ, van Eenbergen MC, de Rooij BH, Bastiaens MT, Fossion LM, de la Fuente RB, Kil PJ, Koldewijn EL, Meier AH, Mommers RJ, Niemer AQ, Oddens JR, Oomens EH, Prins M, de Roos KP, Thissen MR, Timmermans MW, Wijsman BP, **van de Poll-Franse LV, Ezendam NP**. Cancer survivors' preference for follow-up care providers: a cross-sectional study from the population-based PROFILES-registry. *Acta Oncol*. 2017 Feb;56(2):278-287. doi: 10.1080/0284186X.2016.1267398. Epub 2017 Jan 9.
Impactfactor: 3,156

Kieffer JM, Postma TJ, **van de Poll-Franse LV, Mols F**, Heimans JJ, Cavaletti G, Aaronson NK; CI-PeriNomS Group. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). *Qual Life Res*. 2017 Nov;26(11):2999-3010. doi: 10.1007/s11136-017-1626-1. Epub 2017 Jun 20.
Impactfactor: 2,344

Koolen SL, **van der Rijt CC**. Is there a role for pharmacogenetics in the dosing of fentanyl? *Pharmacogenomics*. 2017 Apr;18(5):417-419. doi: 10.2217/pgs-2017-0022. Epub 2017 Mar 27. No abstract available.
Impactfactor: 2,350

Kristjansson RP, Benonisdottir S, Oddsson A, Galesloot TE, Thorleifsson G, **Aben KK**, Davidsson OB, Jonsson S, Arnadottir GA, Jensson BO, Walters GB, Sigurdsson JK, Sigurdsson S, Holm H, Arnar DO, Thorgeirsson G, Alexiusdottir K, Jonsdottir I, Thorsteinsdottir U, Kiemeny LA, Jonsson T, Gudbjartsson DF, Rafnar T, Sulem P, Stefansson K. Sequence variant at 4q25 near PITX2 associates with appendicitis. *Sci Rep*. 2017 Jun 8;7(1):3119. doi: 10.1038/s41598-017-03353-0.
Impactfactor: 4,259

Liang L, Bernhardtsson S, **Vernooij RW**, Armstrong MJ, Bussi eres A, Brouwers MC, Gagliardi AR; Members of the Guidelines International Network Implementation Working Group. *Use of theory to plan or evaluate guideline implementation among physicians: a scoping review*. *Implement Sci*. 2017 Feb 27;12(1):26. doi: 10.1186/s13012-017-0557-0. Review.
Impactfactor: 3,354

Marouli E, Graff M, Medina-Gomez C, Lo KS, Wood AR, Kjaer TR, Fine RS, Lu Y, Schurmann C, Highland HM, R ueger S, Thorleifsson G, Justice AE, Lamparter D, Stirrups KE, Turcot V, Young KL, Winkler TW, Esko T, Karaderi T, Locke AE, Masca NG, Ng MC, Mudgal P, Rivas MA, Vedantam S, Mahajan A, Guo X, Abecasis G, **Aben KK**, Adair LS, Alam DS, Albrecht E, Allin KH, Allison M, Amouyel P, Appel EV, Arveiler D, Asselbergs FW, Auer PL, Balkau B, Banas B, Bang LE, Benn M, Bergmann S, Bielak LF, Bl uher M, Boeing H, Boerwinkle E, B oger CA, Bonnycastle LL, Bork-Jensen J, Bots ML, Bottinger EP, Bowden DW, Brandslund I, Breen G, Brilliant MH, Broer L, Burt AA, Butterworth AS, Carey DJ, Caulfield MJ, Chambers JC, Chasman DI, Chen YI, Chowdhury R, Christensen C, Chu AY, Cocca M, Collins FS, Cook JP, Corley J, Galbany JC, Cox AJ, Cuellar-Partida G, Danesh J, Davies G, de Bakker PI, de Borst GJ, de Denus S, de Groot MC, de Mutsert R, Deary IJ, Dedoussis G, Demerath EW, den Hollander AI, Dennis JG, Di Angelantonio E, Drenos F, Du M, Dunning AM, Easton DF, Ebeling T, Edwards TL, Ellinor PT, Elliott P, Evangelou E, Farmaki AE, Faul JD, Feitosa MF, Feng S, Ferrannini E, Ferrario MM, Ferrieres J, Florez JC, Ford I, Fornage M, Franks PW, Frikke-Schmidt R, Galesloot TE, Gan W, Gandin I, Gasparini P, Giedraitis V, Giri A, Grotto G, Gordon SD, Gordon-Larsen P, Gorski M, Grarup N, Grove ML, Gudnason V, Gustafsson S, Hansen T, Harris KM, Harris TB, Hattersley AT, Hayward C, He L, Heid IM, Heikkil a K, Helgeland  , Hernesniemi J, Hewitt AW, Hocking LJ, Hollensted M, Holmen OL, Hovingh GK, Howson JM, Hoyng CB, Huang PL, Hveem K, Ikram MA, Ingelsson E, Jackson AU, Jansson JH, Jarvik GP, Jensen GB, Jhun MA, Jia Y, Jiang X, Johansson S, J orgensen ME, J orgensen T, Jousilahti P, Jukema JW, Kahali B, Kahn RS, K ah onen M, Kamstrup PR, Kanoni S, Kaprio J, Karaleftheri M, Kardina SL, Karpe F, Kee F, Keeman R, Kiemenev LA, Kitajima H, Kluivers KB, Kocher T, Komulainen P, Kontto J, Kooner JS, Kooperberg C, Kovacs P, Kriebel J, Kuivaniemi H, K ury S, Kuusisto J, La Bianca M, Laakso M, Lakka TA, Lange EM, Lange LA, Langefeld CD, Langenberg C, Larson EB, Lee IT, Lehtim aki T, Lewis CE, Li H, Li J, Li-Gao R, Lin H, Lin LA, Lin X, Lind L, Lindstr om J, Linneberg A, Liu Y, Liu Y, Lophatananon A, Luan J, Lubitz SA, Lyytik ainen LP, Mackey DA, Madden PA, Manning AK, M annist o S, Marenne G, Marten J, Martin NG, Mazul AL, Meidtn er K, Metspalu A, Mitchell P, Mohlke KL, Mook-Kanamori DO, Morgan A, Morris AD, Morris AP, M uller-Nurasyid M, Munroe PB, Nalls MA, Nauck M, Nelson CP, Neville M, Nielsen SF, Nikus K, Nj elstad PR, Nordestgaard BG, Ntalla I, O'Connell JR, Oksa H, Loohuis LM, Ophoff RA, Owen KR, Packard CJ, Padmanabhan S, Palmer CN, Pasterkamp G, Patel AP, Pattie A, Pedersen O, Peissig PL, Peloso GM, Pennell CE, Perola M, Perry JA, Perry JR, Person TN, Pirie A, Polasek O, Posthuma D, Raitakari OT, Rasheed A, Rauramaa R, Reilly DF, Reiner AP, Renstr om F, Ridker PM, Rioux JD, Robertson N, Robino A, Rolandsson O, Rudan I, Ruth KS, Saleheen D, Salomaa V, Samani NJ, Sandow K, Sapkota Y, Sattar N, Schmidt MK, Schreiner PJ, Schulze MB, Scott RA, Segura-Lepe MP, Shah S, Sim X, Sivapalaratnam S, Small KS, Smith AV, Smith JA, Southam L, Spector TD, Speliotes EK, Starr JM, Steinthorsdottir V, Stringham HM, Stumvoll M, Surendran P, 't Hart LM, Tansey KE, Tardif JC, Taylor KD, Teumer A, Thompson DJ, Thorsteinsdottir U, Thuesen BH, T onjes A, Tromp G, Trompet S, Tsafantakis E, Tuomilehto J, Tybjaerg-Hansen A, Tyrer JP, Uher R, Uitterlinden AG, Ulivi S, van der Laan SW, Van Der Leij AR, van Duijn CM, van Schoor NM, van Setten J, Varbo A, Varga TV, Varma R, Edwards DR, Vermeulen SH, Vestergaard H, Vitart V, Vogt TF, Vozzi D, Walker M, Wang F, Wang CA, Wang S, Wang Y, Wareham NJ, Warren HR, Wessel J, Willems SM, Wilson JG, Witte DR, Woods MO, Wu Y, Yaghoobkar H, Yao J, Yao P, Yerges-Armstrong LM, Young R, Zeggini E, Zhan X, Zhang W, Zhao JH, Zhao W, Zhao W, Zheng H, Zhou W; EPIC-InterAct Consortium.; CHD Exome+ Consortium.; ExomeBP Consortium.; T2D-Genes Consortium.; GoT2D Genes Consortium.; Global Lipids Genetics Consortium.; ReproGen Consortium.; MAGIC Investigators.; Rotter JI, Boehnke M, Kathiresan S, McCarthy MI, Willer CJ, Stefansson K, Borecki IB, Liu DJ, North KE, Heard-Costa NL, Pers TH, Lindgren CM, Oxtvig C, Kutalik Z, Rivadeneira F, Loos RJ, Frayling TM, Hirschhorn JN, Deloukas P, Lettre G. *Rare and low-frequency coding variants alter human adult height*. *Nature*. 2017 Feb 9;542(7640):186-190. doi: 10.1038/nature21039.
Impactfactor: 40,137

May AM, Bosch MJ, **Velthuis MJ**, van der Wall E, Steins Bisschop CN, Los M, Erdkamp F, Bloemendal HJ, de Roos MA, Verhaar M, Ten Bokkel Huinink D, Peeters PH, de Wit GA. *Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study*. *BMJ Open*. 2017 Mar 6;7(3):e012187. doi: 10.1136/bmjopen-2016-012187.
Impactfactor: 2,369

Middelburg JG, Mast ME, de Kroon M, Jobsen JJ, Rozema T, Maas H, Baartman EA, Geijssen D, van der Leest AH, van den Bongard DJ, van Loon J, Budiharto T, Coebergh JW, **Aarts MJ**, Struikman H; LPRO (Dutch National Organization for Radiotherapy in the Elderly). Timed Get Up and Go Test and Geriatric 8 Scores and the Association With (Chemo-)Radiation Therapy Noncompliance and Acute Toxicity in Elderly Cancer Patients. *Int J Radiat Oncol Biol Phys*. 2017 Jan 29. pii: S0360-3016(17)30273-0. doi: 10.1016/j.ijrobp.2017.01.211. [Epub ahead of print]
Impactfactor: 5,133

Minicozzi P, Innos K, Sánchez MJ, Trama A, Walsh PM, Marcos-Gragera R, Dimitrova N, Botta L, **Visser O**, Rossi S, Tavilla A, Sant M; EUROCARE-5 Working Group (**Damhuis RA**). Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study. *Eur J Cancer*. 2017 Aug 30;84:335-353. doi: 10.1016/j.ejca.2017.07.015. [Epub ahead of print]
Impactfactor: 6,029

Oldenmenger WH, Baan MA, **van der Rijt CC**. Development and feasibility of a web application to monitor patients' cancer-related pain. *Support Care Cancer*. 2017 Sep 19. doi: 10.1007/s00520-017-3877-3. [Epub ahead of print]
Impactfactor: 2,698

Oosterveld-Vlug M, Donker G, Atsma F, **Brom L**, de Man Y, Groenewoud S, Onwuteaka-Philipsen B. How do treatment aims in the last phase of life relate to hospitalizations and hospital mortality? A mortality follow-back study of Dutch patients with five types of cancer. *Support Care Cancer*. 2017 Sep 22. doi: 10.1007/s00520-017-3889-z. [Epub ahead of print]
Impactfactor: 2,698

Reedijk AM, van der Heiden-van der Loo M, **Visser O**, Karim-Kos HE, Lieverst JA, de Ridder-Sluis JG, Coebergh JW, Kremer LC, Pieters R. Site of childhood cancer care in the Netherlands. *Eur J Cancer*. 2017 Nov 3;87:38-46. doi: 10.1016/j.ejca.2017.09.030. [Epub ahead of print]
Impactfactor: 6,029

Shah VV, Wikramanayake TC, DelCanto GM, **van den Hurk CJ**, Wu S, Lacouture ME, Jimenez JJ. Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials. *J Eur Acad Dermatol Venereol*. 2017 Oct 4. doi: 10.1111/jdv.14612. [Epub ahead of print] Review.
Impactfactor: 3,528

Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, Hesseling P, Shin HY, Stiller CA; IICC-3 contributors (**Visser O**). International incidence of childhood cancer, 2001-10: a population-based registry study. *Lancet Oncol*. 2017 Apr 11. pii: S1470-2045(17)30186-9. doi: 10.1016/S1470-2045(17)30186-9. [Epub ahead of print]
Impactfactor: 33,900

Stouthard J, **Brom L**, **Buiting HM**. Having a Conversation With a Patient With Incurable Cancer-Just Another Protocol? *JAMA Oncol*. 2017 Feb 9. doi: 0.1001/jamaoncol.2016.6776. [Epub ahead of print] No abstract available.
Impactfactor: 16,559

Teepen JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, van den Heuvel-Eibrink MM, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Neggers SJCMM, Jaspers MWM, Hauptmann M, van der Heiden-van der Loo M, **Visser O**, Kremer LCM, Ronckers CM; DCOG LATER Study Group. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. *J Clin Oncol*. 2017 May 22;JCO2016716902. doi: 10.1200/JCO.2016.71.6902. [Epub ahead of print]
Impactfactor: 24,008

Telomeres Mendelian Randomization Collaboration., Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, Wade KH, Timpson NJ, Evans DM, Willeit P, Aviv A, Gaunt TR, Hemani G, Mangino M, Ellis HP, Kurian KM, Pooley KA, Eeles RA, Lee JE, Fang S, Chen WV, Law MH, Bowdler LM, Iles MM, Yang Q, Worrall BB, Markus HS, Hung RJ, Amos CI, Spurdle AB, Thompson DJ, O'Mara TA, Wolpin B, Amundadottir L, Stolzenberg-Solomon R, Trichopoulou A, Onland-Moret NC, Lund E, Duell EJ, Canzian F,

Severi G, Overvad K, Gunter MJ, Tumino R, Svenson U, van Rij A, Baas AF, Bown MJ, Samani NJ, van t'Hof FN, Tromp G, Jones GT, Kuivaniemi H, Elmore JR, Johansson M, McKay J, Scelo G, Carreras-Torres R, Gaborieau V, Brennan P, Bracci PM, Neale RE, Olson SH, Gallinger S, Li D, Petersen GM, Risch HA, Klein AP, Han J, Abnet CC, Freedman ND, Taylor PR, Maris JM, **Aben KK**, Kiemeny LA, Vermeulen SH, Wiencke JK, Walsh KM, Wrensch M, Rice T, Turnbull C, Litchfield K, Paternoster L, Standl M, Abecasis GR, SanGiovanni JP, Li Y, Mijatovic V, Sapkota Y, Low SK, Zondervan KT, Montgomery GW, Nyholt DR, van Heel DA, Hunt K, Arking DE, Ashar FN, Sotoodehnia N, Woo D, Rosand J, Comeau ME, Brown WM, Silverman EK, Hokanson JE, Cho MH, Hui J, Ferreira MA, Thompson PJ, Morrison AC, Felix JF, Smith NL, Christiano AM, Petukhova L, Betz RC, Fan X, Zhang X, Zhu C, Langefeld CD, Thompson SD, Wang F, Lin X, Schwartz DA, Fingerlin T, Rotter JI, Cotch MF, Jensen RA, Munz M, Dommisch H, Schaefer AS, Han F, Ollila HM, Hillary RP, Albagha O, Ralston SH, Zeng C, Zheng W, Shu XO, Reis A, Uebe S, Hüffmeier U, Kawamura Y, Otowa T, Sasaki T, Hibberd ML, Davila S, Xie G, Siminovich K, Bei JX, Zeng YX, Försti A, Chen B, Landi S, Franke A, Fischer A, Ellinghaus D, Flores C, Noth I, Ma SF, Foo JN, Liu J, Kim JW, Cox DG, Delattre O, Mirabeau O, Skibola CF, Tang CS, Garcia-Barcelo M, Chang KP, Su WH, Chang YS, Martin NG, Gordon S, Wade TD, Lee C, Kubo M, Cha PC, Nakamura Y, Levy D, Kimura M, Hwang SJ, Hunt S, Spector T, Soranzo N, Manichaikul AW, Barr RG, Kahali B, Speliotes E, Yerges-Armstrong LM, Cheng CY, Jonas JB, Wong TY, Fogh I, Lin K, Powell JF, Rice K, Relton CL, Martin RM, Davey Smith G. *Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study*. *JAMA Oncol*. 2017 Feb 23. doi: 10.1001/jamaoncol.2016.5945. [Epub ahead of print]
Impactfactor: 16,559

Turcot V, Lu Y, Highland HM, Schurmann C, Justice AE, Fine RS, Bradfield JP, Esko T, Giri A, Graff M, Guo X, Hendricks AE, Karaderi T, Lempradl A, Locke AE, Mahajan A, Marouli E, Sivapalaratnam S, Young KL, Alfred T, Feitosa MF, Masca NGD, Manning AK, Medina-Gomez C, Mudgal P, Ng MCY, Reiner AP, Vedantam S, Willems SM, Winkler TW, Abecasis G, **Aben KK**, Alam DS, Alharthi SE, Allison M, Amouyel P, Asselbergs FW, Auer PL, Balkau B, Bang LE, Barroso I, Bastarache L, Benn M, Bergmann S, Bielak LF, Blüher M, Boehnke M, Boeing H, Boerwinkle E, Böger CA, Bork-Jensen J, Bots ML, Bottinger EP, Bowden DW, Brandslund I, Breen G, Brilliant MH, Broer L, Brumat M, Burt AA, Butterworth AS, Campbell PT, Cappellani S, Carey DJ, Catamo E, Caulfield MJ, Chambers JC, Chasman DI, Chen YI, Chowdhury R, Christensen C, Chu AY, Cocca M, Collins FS, Cook JP, Corley J, Corominas Galbany J, Cox AJ, Crosslin DS, Cuellar-Partida G, D'Eustacchio A, Danesh J, Davies G, Bakker PIW, Groot MCH, Mutsert R, Deary IJ, Dedoussis G, Demerath EW, Heijer M, Hollander AI, Ruijter HM, Dennis JG, Denny JC, Angelantonio E, Drenos F, Du M, Dubé MP, Dunning AM, Easton DF, Edwards TL, Ellinghaus D, Ellinor PT, Elliott P, Evangelou E, Farmaki AE, Farooqi IS, Faul JD, Fauser S, Feng S, Ferrannini E, Ferrieres J, Florez JC, Ford I, Fornage M, Franco OH, Franke A, Franks PW, Friedrich N, Frikke-Schmidt R, Galesloot TE, Gan W, Gandin I, Gasparini P, Gibson J, Giedraitis V, Gjesing AP, Gordon-Larsen P, Gorski M, Grabe HJ, Grant SFA, Grarup N, Griffiths HL, Grove ML, Gudnason V, Gustafsson S, Haessler J, Hakonarson H, Hammerschlag AR, Hansen T, Harris KM, Harris TB, Hattersley AT, Have CT, Hayward C, He L, Heard-Costa NL, Heath AC, Heid IM, Helgeland Ø, Hernesniemi J, Hewitt AW, Holmen OL, Hovingh GK, Howson JMM, Hu Y, Huang PL, Huffman JE, Ikram MA, Ingelsson E, Jackson AU, Jansson JH, Jarvik GP, Jensen GB, Jia Y, Johansson S, Jørgensen ME, Jørgensen T, Jukema JW, Kahali B, Kahn RS, Kähönen M, Kamstrup PR, Kanoni S, Kaprio J, Karaleftheri M, Kardia SLR, Karpe F, Kathiresan S, Kee F, Kiemeny LA, Kim E, Kitajima H, Komulainen P, Kooner JS, Kooperberg C, Korhonen T, Kovacs P, Kuivaniemi H, Kutalik Z, Kuulasmaa K, Kuusisto J, Laakso M, Lakka TA, Lamparter D, Lange EM, Lange LA, Langenberg C, Larson EB, Lee NR, Lehtimäki T, Lewis CE, Li H, Li J, Li-Gao R, Lin H, Lin KH, Lin LA, Lin X, Lind L, Lindström J, Linneberg A, Liu CT, Liu DJ, Liu Y, Lo KS, Lophatananon A, Lotery AJ, Loukola A, Luan J, Lubitz SA, Lyytikäinen LP, Männistö S, Marenne G, Mazul AL, McCarthy MI, McKean-Cowdin R, Medland SE, Meidtner K, Milani L, Mistry V, Mitchell P, Mohlke KL, Moilanen L, Moitry M, Montgomery GW, Mook-Kanamori DO, Moore C, Mori TA, Morris AD, Morris AP, Müller-Nurasyid M, Munroe PB, Nalls MA, Narisu N, Nelson CP, Neville M, Nielsen SF, Nikus K, Njølstad PR, Nordestgaard BG, Nyholt DR, O'Connell JR, O'Donoghue ML, Olde Loohuis LM, Ophoff RA, Owen KR, Packard CJ, Padmanabhan S, Palmer CNA, Palmer ND, Pasterkamp G, Patel AP, Pattie A, Pedersen O, Peissig PL, Peloso GM, Pennell CE, Perola M, Perry JA, Perry JRB, Pers TH, Person TN, Peters A, Petersen ERB, Peyser PA, Pirie A, Polasek O, Polderman TJ, Puolijoki H, Raitakari OT, Rasheed A, Rauramaa R, Reilly DF, Renström F, Rheinberger M, Ridker PM, Rioux JD, Rivas MA, Roberts DJ, Robertson NR, Robino A, Rolandsson O, Rudan I, Ruth KS, Saleheen D, Salomaa V, Samani NJ, Sapkota Y, Sattar N, Schoen RE, Schreiner PJ, Schulze MB, Scott RA, Segura-Lepe MP, Shah SH, Sheu WH, Sim X, Slater AJ, Small KS, Smith AV, Southam L, Spector TD, Speliotes EK, Starr JM, Stefansson K, Steinthorsdottir V, Stirrups KE, Strauch K, Stringham HM, Stumvoll M, Sun L, Surendran P, Swift AJ, Tada H, Tansey KE, Tardif JC, Taylor KD, Teumer A, Thompson DJ, Thorleifsson G, Thorsteinsdottir U, Thuesen BH, Tönjes A, Tromp G, Trompet S,

Tsafantakis E, Tuomilehto J, Tybjaerg-Hansen A, Tyrer JP, Uher R, Uitterlinden AG, Uusitupa M, Laan SW, Duijn CM, Leeuwen N, van Setten J, Vanhala M, Varbo A, Varga TV, Varma R, Velez Edwards DR, Vermeulen SH, Veronesi G, Vestergaard H, Vitart V, Vogt TF, Völker U, Vuckovic D, Wagenknecht LE, Walker M, Wallentin L, Wang F, Wang CA, Wang S, Wang Y, Ware EB, Wareham NJ, Warren HR, Waterworth DM, Wessel J, White HD, Willer CJ, Wilson JG, Witte DR, Wood AR, Wu Y, Yaghoobkar H, Yao J, Yao P, Yerges-Armstrong LM, Young R, Zeggini E, Zhan X, Zhang W, Zhao JH, Zhao W, Zhou W, Zondervan KT; CHD Exome+ Consortium; EPIC-CVD Consortium; ExomeBP Consortium; Global Lipids Genetic Consortium; GoT2D Genes Consortium; EPIC InterAct Consortium; INTERVAL Study; ReproGen Consortium; T2D-Genes Consortium; MAGIC Investigators; Understanding Society Scientific Group, Rotter JJ, Pospisilik JA, Rivadeneira F, Borecki IB, Deloukas P, Frayling TM, Lettre G, North KE, Lindgren CM, Hirschhorn JN, Loos RJF. **Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity.** *Nat Genet.* 2018 Jan;50(1):26-41. doi: 10.1038/s41588-017-0011-x. Epub 2017 Dec 22. Impactfactor: 27,959

van de Poll-Franse LV, Nicolaije KA, Ezendam NP. The impact of cancer survivorship care plans on patient and health care provider outcomes: a current perspective. *Acta Oncol.* 2017 Jan 13:1-5. doi: 10.1080/0284186X.2016.1266080. [Epub ahead of print] Impactfactor: 3,156

van der Hout A, van Uden-Kraan CF, Witte BI, Coupé VMH, Jansen F, Leemans CR, Cuijpers P, **van de Poll-Franse LV**, Verdonck-de Leeuw IM. Efficacy, cost-utility and reach of an eHealth self-management application 'Oncokompas' that helps cancer survivors to obtain optimal supportive care: study protocol for a randomised controlled trial. *Trials.* 2017 May 22;18(1):228. doi: 10.1186/s13063-017-1952-1. Impactfactor: 1,969

van Eenbergen MC, van de Poll-Franse LV, Heine P, **Mols F.** The Impact of Participation in Online Cancer Communities on Patient Reported Outcomes: Systematic Review. *JMIR Cancer.* 2017 Sep 28;3(2):e15. doi: 10.2196/cancer.7312. Impactfactor: 5,175

van Veen MR, Hoedjes M, Versteegen JJ, **van de Meulengraaf-Wilhelm N**, Kampman E, **Beijer S.** Improving Oncology Nurses' Knowledge About Nutrition and Physical Activity for Cancer Survivors. *Oncol Nurs Forum.* 2017 Jul 1;44(4):488-496. doi: 10.1188/17.ONF.488-496. Impactfactor: 1,763

van Waart H, van Dongen JM, van Harten WH, Stuijver MM, Huijsmans R, **Hellendoorn-van Vreeswijk JA**, Sonke GS, Aaronson NK. Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy. *Eur J Health Econ.* 2017 Oct 30. doi: 10.1007/s10198-017-0936-0. [Epub ahead of print] Impactfactor: 2,500

Wachelder JJ, van Drunen I, Stassen PM, Brouns SH, Lamboij SL, **Aarts MJ**, Haak HR. Association of socioeconomic status with outcomes in older adult community-dwelling patients after visiting the emergency department: a retrospective cohort study. *BMJ Open.* 2017 Dec 26;7(12):e019318. doi: 10.1136/bmjopen-2017-019318. Impactfactor: 2,369

Weberpals J, Jansen L, van Herk-Sukel MP, Kuiper JG, **Aarts MJ, Vissers PA**, Brenner H. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis. *Eur J Epidemiol.* 2017 Sep 1. doi: 10.1007/s10654-017-0304-5. [Epub ahead of print] Impactfactor: 7,226

Zanders MM, Haak HR, van Herk-Sukel MP, Herings RM, **van de Poll-Franse LV**, Johnson JA. Changes in glucose-lowering drug use before and after cancer diagnosis in patients with diabetes. *Diabetes Metab.* 2017 Oct 21. pii: S1262-3636(17)30509-8. doi: 10.1016/j.diabet.2017.08.004. [Epub ahead of print] Impactfactor: 4,101

1.2 Overige publicaties

Clark J, **Raijmakers NJ**, Allan S, Zuylen LV, Heide AV. Declining oral intake towards the end of life: how to talk about it? A qualitative study. *Int J Palliat Nurs*. 2017 Feb 2;23(2):74-82. doi: 10.12968/ijpn.2017.23.2.74.

Mackenbach JP, **Damhuis RA**, Been JV. De gezondheidseffecten van roken: groei van kennis leidt tot steeds grimmiger beeld. *Ned Tijdschr Geneeskd*. 2017;161:D869.

Roelofs E, **Demmer B**. Veilig omgaan met cytostatica. *Huisarts en wetenschap* 2017 juni;60(6):3.

1.3 Boeken en boekbijdragen

van Eycken L, Henau K, **Visser O**, **Siesling S**. Kankerepidemiologie : incidentie, prevalentie, sterfte en verwachtingen. In: *Oncologie : praktische huisartsgeneeskunde (hoofdstuk 1)*. Houten : Bohn Stafleu Van Loghum, 2017.

1.4 Posters

Fransen HP, **Raijmakers NJ**, **Lokker ME**, **Brom L**, van der Linden YM, Teunissen CC, Wartenberg HC, Reyners AK, Francke AL. Care provided to cancer patients in their last month of life: a retrospective study in patients who died in Dutch university hospitals. EAPC, European Association for Palliative Care; 18-20 mei 2017; Madrid.

Raijmakers NJ, **Fransen HP**, **Lokker ME**, **Brom L**, van der Heide A, Onwuteaka-Philipsen B, Janssen DJ, Engels Y, Francke AL, Reyners AK. Advance care planning for cancer patients: a retrospective chart review in patients who died in a Dutch university hospital. EAPC, European Association for Palliative Care; 18-20 mei 2017; Madrid.

Siesling S, **Verloop J**, **Verbeek X**, Schade K, **Visser O**, **Lemmens VE**. Quality improvement by online feedback from the Netherlands Cancer Registry-NCR online. PHE National Cancer Registration and Analysis Service (NCRAS) congres; 13-14 juni 2017; Manchester.

van den Hurk CJ, **van Eenbergen MC**, Coolbrandt A, Young A. Coping with side effects of systemic anti-cancer treatment: patient-reported monitoring and subsequent interventions. MASCC/ISOO annual meeting, Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology; 22-24 juni 2017; Washington.

van der Mark M, Husson O, Bijlsma RM, Westermann A, **Karim-Kos H**, **Aben KK**, van der Graaf WT. Incidence and survival trends of cancers diagnosed in adolescents and young adults (15-39 years): a population-based study in the Netherlands. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

1.5 Presentaties en abstracts

Beijers AJ, **Mols F**, Ophorst J, Pijs J, de Vos-Geelen J, Jacobs E, **van de Poll-Franse LV**, Vreugdenhil G. Multicenter randomized controlled trial to evaluate the efficacy of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy. ESMO Congress; 8-12 september; Madrid.

Cocks K, Tolley C, Grant L, Wheelwright S, Tomaszewski K, Groenvold M, Bottomley A, Fitzsimmons D, Velikova G, **Oerlemans S**, Arraras JI, Aaronson NK, Johnson CD. Generation of evidence to support the content validity of legacy quality of life instruments: EORTC QLQ-C30 case study. ISOQOL Annual Conference, International Society for Quality of Life Research; 18-21 oktober 2017; Philadelphia.

de Rooij BH, **Ezendam NP**, **Mols F**, **Vissers PA**, Thong MS, **Vlooswijk C**, **Oerlemans S**, Husson O, **Horevoorts NJ**, **van de Poll-Franse LV**. Do patient-reported outcome studies paint too rosy pictures?: systematic underrepresentation of patients with lower survival: the population-based profiles registry. MASCC/ISOO annual meeting, Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology; 22-24 juni 2017; Washington.

Husson O, **van der Mark M**, Bijlsma R, Westermann AM, **Aben KK**, van der Graaf WT. Incidence and survival trends of cancers diagnosed in young adults (20-39 years): a population-based study. ASCO Annual Meeting, American Society of Clinical Oncology; 2-6 juni 2017; Chicago.

Kulis D, Bottomley A, Whittaker C, **van de Poll-Franse LV**, Darlington A, Holzner B, Koller M, Reijneveld JC, Tomaszewski K, Grønvold M. The use of the EORTC item library to supplement EORTC quality of life instruments. ISPOR annual European Congress, the International Society for Pharmacoeconomics and Outcomes Research; 4-8 november 2017; Glasgow.

Mayberry S, Young A, **van den Hurk CJ**. Cool across the globe: research, practice and experiences. International Conference on Cancer Nursing (ICCN); 9-12 juli 2017; Californië.

Siesling S. Mind the gap: elderly cancer patients lack behind in gain in survival. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

Siesling S. Prediction model of follow-up in breast cancer and possible consequences for care. International Congress of Breast Disease Centers; 13-14 oktober 2017; Aken.

Swan, GM, Langendam M, Weyler J, Burger H, **Siesling S**, Atsma WJ, Bouter L. Responsible Epidemiologic Research Practice. Federadag; 16 juni 2017; Den Haag.

Tomalin B, Pearce A, Kaambwa B, **Horevoorts NJ**, Duijts S, Mols F, **van de Poll-Franse LV**, Koczwara B. Financial toxicity, employment and quality of life of cancer survivors: a secondary analysis of the profiles registry. COSA Annual Scientific Meeting, Clinical Oncology Society of Australia; 13-15 november 2017; Sydney.

van den Hurk CJ. Advances in scalp cooling research from the Netherlands. MASCC/ISOO annual meeting, Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology; 22-24 juni 2017; Washington.

van den Hurk CJ, van Eenbergen MC, Coolbrandt A, Young A. Coping with side effects of systemic anti-cancer treatment: patient-reported monitoring and subsequent interventions. MASCC/ISOO annual meeting, Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology; 22-24 juni 2017; Washington.

van den Hurk CJ. Scalp cooling awareness campaign in the Netherlands. Symposium Cancer Management, Sysmex; 25 februari 2017; Hamburg.

Versteeg S. Centralisation of cancer surgery and the impact on patients' travel burden. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

Young A, **van den Hurk CJ**. Science & clinical update: review of scalp cooling studies 'The time has come'. Scalp Cooling Masterclass; 17 februari 2017; Londen.

2 Borstkanker

2.1 Publicaties met impactfactor

Bastiaannet E, Charman J, Johannesen TB, Schrodi S, **Siesling S**, van Eycken L, Walsh PM, Audisio RA, Boelens PG, Rubio IT, Jones N, Lewis J, van de Velde CJ. A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer. *Clin Breast Cancer*. 2017 Nov 29. pii: S1526-8209(17)30728-0. doi: 10.1016/j.clbc.2017.11.019. [Epub ahead of print]
Impactfactor: 2,816

Dackus GM, Ter Hoeve ND, Opdam M, Vreuls W, Varga Z, Koop E, Willems SM, Van Deurzen CH, Groen EJ, Cordoba A, Bart J, Mooyaart AL, van den Tweel JG, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Amant F, Broeks A, Kerkhoven R, Stathonikos N, Veta M, **Voogd AC**, Jozwiak K, Hauptmann M, Hoogstraat M, Schmidt MK, Sonke G, van der Wall E, **Siesling S**, van Diest PJ, Linn SC. Long-term prognosis of young breast cancer patients (≤ 40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. *BMJ Open*. 2017 Nov 14;7(11):e017842. doi: 10.1136/bmjopen-2017-017842.
Impactfactor: 2,369

Dackus GM, Józwiak K, Sonke GS, van der Wall E, van Diest PJ, Hauptmann M, **Siesling S**, Linn SC. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study. *Eur J Cancer*. 2017 Dec 21;90:92-101. doi: 10.1016/j.ejca.2017.11.010. [Epub ahead of print]
Impactfactor: 6,029

de Ligst KM, Spronk PE, van Bommel AC, Vrancken Peeters MT, **Siesling S**, Smorenburg CH; Nabon Breast Cancer Audit group. Patients' experiences with decisions on timing of chemotherapy for breast cancer. *Breast*. 2017 Nov 9;37:99-106. doi: 10.1016/j.breast.2017.10.016. [Epub ahead of print]
Impactfactor: 2,801

de Munck L, **Siesling S**. Re: Effectiveness of and overdiagnosis from mammography screening in the Netherlands: population based study. *BMJ* 2017;359:j5224.
Impactfactor: 20,785

Elshof LE, Schaapveld M, Rutgers EJ, Schmidt MK, **de Munck L**, van Leeuwen FE, Wesseling J. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study. *Breast Cancer Res*. 2017 Mar 9;19(1):26. doi: 10.1186/s13058-017-0819-4.
Impactfactor: 6,345

Engelhardt EG, van den Broek AJ, Linn SC, Wishart GC, Rutgers EJT, van de Velde AO, Smit VTHBM, **Voogd AC**, **Siesling S**, Brinkhuis M, Seynaeve C, Westenend PJ, Stiggelbout AM, Tollenaar RAEM, van Leeuwen FE, van 't Veer LJ, Ravdin PM, Pharaoh PDP, Schmidt MK. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. *Eur J Cancer*. 2017 Apr 13;78:37-44. doi: 10.1016/j.ejca.2017.03.015. [Epub ahead of print]
Impactfactor: 6,029

Geurts YM, Witteveen A, **Bretveld R**, Poortmans PM, Sonke GS, Strobbe LJ, **Siesling S**. Patterns and predictors of first and subsequent recurrence in women with early breast cancer. *Breast Cancer Res Treat*. 2017 Jul 4. doi: 10.1007/s10549-017-4340-3. [Epub ahead of print]
Impactfactor: 3,626

Goorts B, van Nijnatten TJ, **de Munck L**, Moosdorff M, Heuts EM, de Boer M, Lobbes MB, Smidt ML. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. *Breast Cancer Res Treat*. 2017 Feb 15. doi: 10.1007/s10549-017-4155-2. [Epub ahead of print]
Impactfactor: 3,626

Kuijer A, Straver M, den Dekker B, van Bommel AC, Elias SG, Smorenburg CH, Wesseling J, Linn SC, Rutgers EJ, **Siesling S**, van Dalen T. Impact of 70-Gene Signature Use on Adjuvant Chemotherapy

Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study. *J Clin Oncol*. 2017 March 13. doi: 10.1200/JCO.2016.70.3959. Impactfactor: 24,008

Kuijter A, **Verloop J**, **Visser O**, Sonke G, Jager A, van Gils CH, van Dalen T, Elias SG. The influence of socio-economic status and ethnicity on adjuvant systemic treatment guideline adherence for early stage breast cancer in the Netherlands. *Ann Oncol*. 2017 Apr 29. doi: 10.1093/annonc/mdx204. [Epub ahead of print] Impactfactor: 11,855

Legendijk M, **van Maaren MC**, Saadatmand S, Strobbe LJA, Poortmans PMP, Koppert LB, Tilanus-Linthorst MMA, **Siesling S**. Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients. *Int J Cancer*. 2017 Sep 7. doi: 10.1002/ijc.31034. [Epub ahead of print] Impactfactor: 6,513

Lobbes MB, Vriens IJ, van Bommel AC, Nieuwenhuijzen GA, Smidt ML, Boersma LJ, van Dalen T, Smorenburg C, Struikmans H, **Siesling S**, **Voogd AC**, Tjan-Heijnen VC. Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. *Breast Cancer Res Treat*. 2017 Jan 28. doi: 10.1007/s10549-017-4117-8. [Epub ahead of print] Impactfactor: 3,626

Luiten JD, **Voogd AC**, Luiten EJ, Duijm LE. Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer. *Breast Cancer Res Treat*. 2017 Jul 26. doi: 10.1007/s10549-017-4412-4. [Epub ahead of print] Impactfactor: 3,626

Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, Oosterhuis WJ, Wesseling J, Janssen-Heijnen ML, Jobsen JJ, Jager A, **Voogd AC**, van Leeuwen FE, van 't Veer LJ. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. *J Natl Cancer Inst*. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw329. Impactfactor: 12,589

Schoormans D, **van de Poll-Franse LV**, **Vissers PA**, van Herk-Sukel MP, Pedersen SS, Rottmann N, Horsbøl T, Dalton S, Denollet J. Pharmaceutically treated anxiety but not depression prior to cancer diagnosis predicts the onset of cardiovascular disease among breast cancer survivors. *Breast Cancer Res Treat*. 2017 Jul 17. doi: 10.1007/s10549-017-4387-1. [Epub ahead of print] Impactfactor: 3,626

Schreuder K, van Bommel ACM, **de Ligt KM**, Maduro JH, Vrancken Peeters MTFD, Mureau MAM, **Siesling S**. Hospital organizational factors affect the use of immediate breast reconstruction after mastectomy for breast cancer in the Netherlands. *Breast*. 2017 May 24;34:96-102. doi: 10.1016/j.breast.2017.05.011. [Epub ahead of print] Impactfactor: 2,801

Schreuder K, Kuijter A, Rutgers EJ, Smorenburg CH, van Dalen T, **Siesling S**. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area. *Eur J Cancer*. 2017 Aug 23;84:270-277. doi: 10.1016/j.ejca.2017.07.042. [Epub ahead of print] Impactfactor: 6,029

Spronk PE, van Bommel AC, **Siesling S**, Wouters MW, Vrancken Peeters MT, Smorenburg CH. Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: Results of the Dutch national breast cancer audit. *Breast*. 2017 Sep 20;36:34-38. doi: 10.1016/j.breast.2017.08.011. [Epub ahead of print] Impactfactor: 2,801

Tjan-Heijnen VC, van Hellemond IE, Peer PG, **Swinkels AC**, Smorenburg CH, van der Sangen MJ, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FL, van den Berkmoortel FW, de Boer M, de Roos WK, Linn SC, Imholz AL, Seynaeve CM; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase

3 trial. *Lancet Oncol.* 2017 Oct 11. pii: S1470-2045(17)30600-9. doi: 10.1016/S1470-2045(17)30600-9. [Epub ahead of print]
Impactfactor: 33,900

Truin W, Roumen RM, **Siesling S**, van de Vijver KK, Tjan-Heijnen VC, **Voogd AC**. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. *Breast Cancer Res Treat.* 2017 Apr 1. doi: 10.1007/s10549-017-4220-x. [Epub ahead of print]
Impactfactor: 3,626

van Bommel RMG, Weber R, **Voogd AC**, Nederend J, **Louwman MW**, Venderink D, Strobbe LJA, Rutten MJC, Plaisier ML, Lohle PN, Hooijen MJH, Tjan-Heijnen VCG, Duijm LEM. Interval breast cancer characteristics before, during and after the transition from screen-film to full-field digital screening mammography. *BMC Cancer.* 2017 May 5;17(1):315. doi: 10.1186/s12885-017-3294-5.
Impactfactor: 3,288

van Maaren MC, **Bretveld RW**, Jobsen JJ, Veenstra RK, Groothuis-Oudshoorn CG, Struikmans H, Maduro JH, Strobbe LJ, Poortmans PM, **Siesling S**. The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival. *Br J Cancer.* 2017 Jun 6. doi: 10.1038/bjc.2017.159. [Epub ahead of print]
Impactfactor: 6,176

van Maaren MC, **van Steenbeek CD**, Pharoah PD, Witteveen A, Sonke GS, Strobbe LJA, Poortmans PM, **Siesling S**. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population. *Eur J Cancer.* 2017 Nov;86:364-372. doi: 10.1016/j.ejca.2017.09.031. Epub 2017 Nov 5.
Impactfactor: 6,029

van Nijnatten TJ, Simons JM, Moosdorff M, **de Munck L**, Lobbes MB, van der Pol CC, Koppert LB, Luiten EJ, Smidt ML. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases. *Breast Cancer Res Treat.* 2017 Feb 17. doi: 10.1007/s10549-017-4157-0. [Epub ahead of print]
Impactfactor: 3,626

van Nijnatten TJ, Moosdorff M, **de Munck L**, Goorts B, Vane MLG, Keymeulen KBMI, Beets-Tan RGH, Lobbes MBI, Smidt ML. TNM classification and the need for revision of pN3a breast cancer. *Eur J Cancer.* 2017 Jul;79:23-30. doi: 10.1016/j.ejca.2017.04.002.
Impactfactor: 6,029

van Uden DJ, **Bretveld R**, **Siesling S**, de Wilt JH, Blanken-Peeters CF. Inflammatory breast cancer in the Netherlands; improved survival over the last decades. *Breast Cancer Res Treat.* 2017 Jan 30. doi: 10.1007/s10549-017-4119-6. [Epub ahead of print]
Impactfactor: 3,626

van Vulpen JK, Schmidt ME, **Velthuis MJ**, Wiskemann J, Schneeweiss A, Vermeulen RCH, Habermann N, Ulrich CM, Peeters PH, van der Wall E, May AM, Steindorf K. Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy. *Breast Cancer Res Treat.* 2017 Dec 12. doi: 10.1007/s10549-017-4608-7. [Epub ahead of print]
Impactfactor: 3,626

Verheuel NC, **Voogd AC**, Tjan-Heijnen VC, **Siesling S**, Roumen RM. Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure. *Breast Cancer Res Treat.* 2017 Jun 27. doi: 10.1007/s10549-017-4342-1. [Epub ahead of print]
Impactfactor: 3,626

Verheuel NC, **Voogd AC**, Tjan-Heijnen VC, **Siesling S**, Roumen RM. Non-visualized sentinel nodes in breast cancer patients; prevalence, risk factors, and prognosis. *Breast Cancer Res Treat.* 2017 Aug 31. doi: 10.1007/s10549-017-4483-2. [Epub ahead of print]
Impactfactor: 3,626

Verheuveel NC, **Voogd AC**, Tjan-Heijnen VC, Roumen RM. What to Do with Non-visualized Sentinel Nodes? A Dutch Nationwide Survey Study. *Ann Surg Oncol*. 2017 Mar 3. doi: 10.1245/s10434-017-5824-4. [Epub ahead of print]
Impactfactor: 4,041

Vos EL, **Siesling S**, Baaijens MH, Verhoef C, Jager A, **Voogd AC**, Koppert LB. Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival. *Breast Cancer Res Treat*. 2017 Apr 7. doi: 10.1007/s10549-017-4232-6. [Epub ahead of print]
Impactfactor: 3,626

Vriens BE, Vriens IJ, Aarts MJ, **van Gastel SM**, van den Berkmortel FW, Smilde TJ, van Warmerdam LJ, van Spronsen DJ, Peer PG, de Boer M, Tjan-Heijnen VC; Breast Cancer Trialists' Group of the Netherlands (BOOG). Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. *Breast Cancer Res Treat*. 2017 Oct;165(3):593-600. doi: 10.1007/s10549-017-4364-8. Epub 2017 Jul 3.
Impactfactor: 3,626

Vriens IJH, Keymeulen K, Lobbes MBI, van Bommel ACM, Nieuwenhuijzen GAP, Smidt ML, Boersma LJ, van Dalen T, Smorenburg CH, Struikmans H, **Siesling S**, **Voogd AC**, Tjan-Heijnen VCG; National Breast Cancer Organization of the Netherlands – Breast Cancer Audit Scientific Committee (NBCA). Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers. *Eur J Cancer*. 2017 Jun 12;81:74-80. doi: 10.1016/j.ejca.2017.05.012. [Epub ahead of print]
Impactfactor: 6,029

2.2 Overige publicaties

Siesling S. Risico op borst-of ovariumkanker bij BRCA 1/2-draagsters. *Ned Tijdsch Geneesk*. 2017;161:D2020.

2.3 Boeken en boekbijdragen

Otten JW, Witteveen A, Vliegen IM, **Siesling S**, Timmer JB, IJzerman MJ. Stratified breast cancer follow-up using a partially observable MDP. In: Markov decision processes in practice (hoofdstuk 7). Cham : Springer, 2017.

2.4 Posters

de Ligt KM, Spronk PE, van Bommel AC, Vrancken Peeters MT, **Siesling S**, Smorenburg CH. Patient experiences with shared decision-making on neoadjuvant chemotherapy in early breast cancer. WEON congress, Epidemiological Methods for Implementation Research; 8-9 juni; Antwerpen.

de Munck L, Fracheboud J, de Bock GH, den Heeten GJ, **Siesling S**, Broeders MJ. Advanced stage breast cancer is less often diagnosed in women who attend breast cancer screening. Sankt Gallen International Breast Cancer Conference; 15-18 maart 2017; Wenen.

van Uden, DJ, **van Maaren MC**, Bult P, Blanken-Peeters CF, **Siesling S**, de Wilt JH. Molecular subtypes in inflammatory breast cancer: a descriptive analysis using the Netherlands Cancer Registry. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht

2.5 Presentaties en abstracts

Dackus GM, Jozwiak K, van der Wall E, van Diest PJ, Hauptmann M, **Siesling S**, Sonke GS, Linn SC. Adjuvant treatment of HER2+ breast cancer: should trastuzumab be given sequentially or concurrently with chemotherapy? San Antonio Breast Cancer Symposium; 5-9 december 2017; San Antonio.

Dackus GM, ter Hoeve ND, Opdam M, Stathonikos N, Belien JA, Wesseling J, Broeks A, van der Wall E, Rousseau J, **Siesling S**, Sonke GS, Linn SC, van Diest PJ. Biobanking incorporating digital pathology to accomplish large-scale clinicopathological projects: the PARADIGM experience. Global Biobank Week; 13-15 september 2017; Stockholm.

Dackus GM, ter Hoeve ND, Opdam M, Vreuls W, Koop EA, Willems SM, Varga Z, Cordoba-Iturriagagoitia A, Mooyaart AL, Groen EJ, Broeks A, Stathonikos N, Jozwiak K, Hauptmann M, Sonke GS, van der Wall E, **Siesling S**, van Diest PJ, Linn SC. Long-term outcome of breast cancer patients diagnosed ≤ 40 years according to breast cancer subtype in the absence of adjuvant systemic therapy: the PARADIGM initiative. ASCO Annual Meeting, American Society of Clinical Oncology; 2-6 juni 2017; Chicago.

de Ligt, KM. Patients' experiences with decisions on timing of chemotherapy for breast cancer. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

de Munck L, Fracheboud J, de Bock GH, **Siesling S**, Broeders MJ. Advanced stage breast cancer is less often diagnosed in women who attend breast cancer screening. Sankt Gallen International Breast Cancer Conference; 15-18 maart 2017; Wenen.

Lagendijk M, **van Maaren MC**, Saadatmand S, Strobbe LJ, Poortmans PM, Koppert LB, Tilanus-Linthorst MM, **Siesling S**. Breast conserving therapy and mastectomy revisited: breast cancer-specific survival and the influence of prognostic factors in 129,692 patients. ECCO, European Cancer Congress; 27-30 januari 2017; Amsterdam.

Lagendijk M, **van Maaren MC**, Saadatmand S, Strobbe LJ, Poortmans PM, Koppert LB, Tilanus-Linthorst MM, **Siesling S**. Mammaspurende therapie en mastectomie herbeoordeeld: borstkankerspecifieke overleving en de invloed van prognostische factoren in 129,692 patiënten. Chirurgendagen; 11-12 mei 2017; Veldhoven.

Rombouts AJ, Huising J, Hugen N, **Siesling S**, de Wilt JH, Poortmans PM, Nagtegaal ID. Radiation therapy associated sarcoma after breast cancer treatment: a population-based study. SSO annual cancer symposium, The society of surgical oncology; 15-18 maart 2017; Seattle.

Siesling S, Verbeek X, Schade K, Visser o, Lemmens VE. Quality improvement by online feedback from the Netherlands Cancer Registry. EPH, European Public Health Conference; 1-4 november 2017; Stockholm.

van Maaren MC, **van Steenbeek CD**, Pharoah, PD, Witteveen A, Sonke GS, Strobbe LJ, Poortmans PM, **Siesling S**. Validation of the online prediction tool PREDICT v.2.0: a large population-based study in the Netherlands. San Antonio Breast Cancer Symposium; 5-9 december 2017; San Antonio.

van Maaren MC, **Verhoeven RH**, Kneepkens RF, Verbaan JJ, **Huijgens PC**, **Lemmens VE**, **Siesling S**. When will a breast cancer patient be cured?: a prediction model for conditional relative survival. WEON congress, Epidemiological Methods for Implementation Research; 8-9 juni; Antwerpen.

van Nijnatten T, Habraken V, Aarnoutse R, **de Munck L**, Moosdorff M, Heuts E, Lobbes M, Smidt M. Does the TNM classification of solitary internal mammary lymph node metastases in breast cancer still apply? SSO annual cancer symposium, The society of surgical oncology; 15-18 maart 2017; Seattle.

van Steenhoven JE, Kuijer A, **Schreuder K**, van Bommel AC, Elias S, Smorenburg C, Linn S, Rutgers E, **Siesling S**, van Dalen T. Impact of the 70-gene signature on chemotherapy administration in Dutch early stage breast cancer patients. SSO annual cancer symposium, The society of surgical oncology; 15-18 maart 2017; Seattle.

van Uden DJ, **van Maaren MC**, Bult P, Blanken-Peeters CF, **Siesling S**, de Wit JH. Molecular subtypes in inflammatory breast cancer: a descriptive analysis using the Netherlands Cancer Registry. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

Vane M, Willemsen M, van Roozendaal L, van Kuijk S, Kooreman L, **Siesling S**, Engelen S, de Wilt H, Smidt M. Extracapsular extension of sentinel lymph node: a marker of poor prognosis in CT1-2N0 breast cancer patients? SSO annual cancer symposium, The society of surgical oncology; 15-18 maart 2017; Seattle.

Vane M, van Roozendaal L, van Kuijk S, **Siesling S**, de Wilt H, Smidt M. Treatment of elderly cT1-2N0 breast cancer patients: can omission of sentinel lymph node biopsy be combined with whole breast irradiation? SSO annual cancer symposium, The society of surgical oncology; 15-18 maart 2017; Seattle.

Versteeg SE, **Ho, VK, Siesling S**, Varkevisser M. Centralisation of cancer surgery and the impact on patients' travel burden. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

Visser O, Wauben B, **Siesling S**. Mind the gap: patients with metastatic disease lack behind in gain in survival. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

Witteveen A, **de Munck L**, Groothuis C, Poortmans P, Boersma L, Vliegen I, Sonke GS, Smidt L, Klaase J, IJzerman M, **Siesling S**. Recurrence risk and risk-based follow-up after breast cancer treatment. CHOIR symposium; 13-15 december 2017; Enschede.

3 Bot-en wekedelentumoren

3.1 Publicaties met impactfactor

Hoekstra HJ, Haas RL, Verhoef C, Suurmeijer AJ, van Rijswijk CS, Bongers BG, van der Graaf WT, **Ho VK**. Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers. *Ann Surg Oncol*. 2017 Jul 26. doi: 10.1245/s10434-017-6003-3. [Epub ahead of print]
Impactfactor: 4,041

Pasquali S, Bonvalot S, Tzanis D, Casali PG, Trama A, Gronchi A; RARECARENet Working Group (**Visser O**). Treatment challenges in and outside a network setting: Soft tissue sarcomas. *Eur J Surg Oncol*. 2017 Sep 19. pii: S0748-7983(17)30705-9. doi: 10.1016/j.ejso.2017.09.015. [Epub ahead of print]
Impactfactor: 3,522

4 Darmkanker

4.1 Publicaties met impactfactor

Babaei M, Balavarca Y, Jansen L, **Lemmens VE, van Erning FN**, van Eycken L, Vaes E, Sjövall A, Glimelius B, Ulrich CM, Schrotz-King P, Brenner H. Administration of Adjuvant Chemotherapy for Stage II-III Colon Cancer Patients: A European Population-based Study. *Int J Cancer*. 2017 Nov 21. doi: 10.1002/ijc.31168. [Epub ahead of print]
Impactfactor: 6,513

Babaei M, Jansen L, Balavarca Y, Sjövall A, **Bos AC**, van de Velde T, Moreau M, Liberale G, Gonçalves AF, Bento MJ, Ulrich CM, Schrotz-King P, **Lemmens VE**, Glimelius B, Brenner H. Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes. *Clin Colorectal Cancer*. 2017 Sep 28. pii: S1533-0028(17)30050-6. doi: 10.1016/j.clcc.2017.09.002. [Epub ahead of print]
Impactfactor: 4,507

Bos AC, Matthijsen RA, **van Erning FN, van Oijen MG**, Rutten HJ, **Lemmens VE**. Treatment and Outcome of Synchronous Colorectal Carcinomas: A Nationwide Study. *Ann Surg Oncol*. 2017 Nov 20. doi: 10.1245/s10434-017-6255-y. [Epub ahead of print]
Impactfactor: 4,041

Derksen TM, Bours MJ, **Mols F**, Weijenberg MP. Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review. *Evid Based Complement Alternat Med*. 2017;2017:7916031. doi: 10.1155/2017/7916031. Epub 2017 Mar 16. Review.
Impactfactor: 1,740

Franken MD, van Rooijen EM, May AM, Koffijberg H, van Tinteren H, **Mol L**, Ten Tije AJ, Creemers GJ, van der Velden AM, Tanis BC, Uyl-de Groot CA, Punt CJ, Koopman M, van Oijen MG. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. *Eur J Cancer*. 2017 Feb 23;75:204-212. doi: 10.1016/j.ejca.2017.01.019. [Epub ahead of print]
Impactfactor: 6,029

Frouws MA, Rademaker E, Bastiaannet E, van Herk-Sukel MP, **Lemmens VE**, Van de Velde CJ, Portielje JE, Liefers GJ. The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer. *Eur J Cancer*. 2017 Mar 25;77:24-30. doi: 10.1016/j.ejca.2017.02.025. [Epub ahead of print]
Impactfactor: 6,029

Frouws MA, Reimers MS, Swets M, Bastiaannet E, Prinse B, van Eijk R, **Lemmens VE**, van Herk-Sukel MP, van Wezel T, Kuppen PJ, Morreau H, van de Velde CJ, Liefers GJ. The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis. *PLoS One*. 2017 Jan 26;12(1):e0170775. doi: 10.1371/journal.pone.0170775.
Impactfactor: 2,806

Hoedjes M, de Kruif A, **Mols F**, Bours M, **Beijer S**, Winkels R, Westerman MJ, Seidell JC, Kampman E. An exploration of needs and preferences for dietary support in colorectal cancer survivors: A mixed-methods study. *PLoS One*. 2017 Dec 18;12(12):e0189178. doi: 10.1371/journal.pone.0189178. eCollection 2017.
Impactfactor: 2,806

Jansen L, Weberpals J, Kuiper JG, **Vissers PA**, Wolkewitz M, Hoffmeister M, Brenner H. Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: Results from a population-based study. *Int J Cancer*. 2017 Apr 1. doi: 10.1002/ijc.30717. [Epub ahead of print]
Impactfactor: 6,513

Keikes L, Koopman M, Tanis PJ, **Lemmens VE**, Punt CJA, van Oijen MG. Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review. *Eur J Cancer*. 2017 Oct 5;86:166-177. doi: 10.1016/j.ejca.2017.08.034. [Epub ahead of print] Review.

Impactfactor: 6,029

Keikes L, van Oijen MG, **Lemmens VE**, Koopman M, Punt CJ. Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group. *Clin Colorectal Cancer*. 2017 Nov 17. pii: S1533-0028(17)30022-1. doi: 10.1016/j.clcc.2017.10.007. [Epub ahead of print]
Impactfactor: 4,507

Kwakman JJ, **Vink GR**, Vestjens JH, Beerepoot LV, de Groot JW, Jansen RL, Opdam FL, Boot H, Creemers GJ, van Rooijen JM, Los M, Vulink AJ, Schut H, van Meerten E, Baars A, Hamberg P, Kapiteijn E, Sommeijer DW, Punt CJ, Koopman M. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. *Int J Clin Oncol*. 2017 Dec 4. doi: 10.1007/s10147-017-1220-0. [Epub ahead of print]
Impactfactor: 2,064

Kwakman JJ, Simkens LH, van Rooijen JM, van de Wouw AJ, Ten Tije AJ, Creemers GJ, Hendriks MP, Los M, van Alphen RJ, Polée MB, Muller EW, van der Velden AM, van Voorthuizen T, Koopman M, **Mol L**, van Werkhoven E, Punt CJ. Randomised phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. *Ann Oncol*. 2017 Apr 5. doi: 10.1093/annonc/mdx122. [Epub ahead of print]
Impactfactor: 11,855

Lamkaddem M, **Elferink MA**, Seeleman MC, Dekker E, Punt CJA, **Visser O**, Essink-Bot ML. Ethnic differences in colon cancer care in the Netherlands: a nationwide registry-based study. *BMC Cancer*. 2017 May 4;17(1):312. doi: 10.1186/s12885-017-3241-5.
Impactfactor: 3,288

Legué LM, Simkens GA, Creemers GM, **Lemmens VE**, de Hingh IH. Synchronous peritoneal metastases of small bowel adenocarcinoma: Insights into an underexposed clinical phenomenon. *Eur J Cancer*. 2017 Nov 10;87:84-91. doi: 10.1016/j.ejca.2017.10.012. [Epub ahead of print]
Impactfactor: 6,029

Rovers KP, Simkens GA, **Vissers PA**, **Lemmens VE**, Verwaal VJ, Bremers AJ, Wiezer MJ, Burger JW, Hemmer PH, Boot H, van Grevenstein WM, Meijerink WJ, Aalbers AG, Punt CJ, Tanis PJ, de Hingh IH; Dutch Peritoneal Oncology Group (DPOG). Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study. *Eur J Cancer*. 2017 Feb 17;75:132-140. doi: 10.1016/j.ejca.2016.12.034. [Epub ahead of print]
Impactfactor: 6,029

Schoormans D, Husson O, Denollet J, **Mols F**. Is Type D personality a risk factor for all-cause mortality? A prospective population-based study among 2625 colorectal cancer survivors from the PROFILES registry. *J Psychosom Res*. 2017 May;96:76-83. doi: 10.1016/j.jpsychores.2017.03.004. Epub 2017 Mar 14.
Impactfactor: 2,809

Toes-Zoutendijk E, Kooyker AI, **Elferink MA**, Spaander MCW, Dekker E, Koning HJ, **Lemmens VE**, van Leerdam ME, Lansdorp-Vogelaar I; LECO working group. Stage distribution of screen-detected colorectal cancers in the Netherlands. *Gut*. 2017 Oct 21. pii: gutjnl-2017-315111. doi: 10.1136/gutjnl-2017-315111. [Epub ahead of print] No abstract available.
Impactfactor: 16,658

Thong MS, **Mols F**, **van de Poll-Franse LV**, Sprangers MA, van der Rijt CC, Barsevick AM, Knoop H, Husson O. Identifying the subtypes of cancer-related fatigue: results from the population-based PROFILES registry. *J Cancer Surviv*. 2017 Sep 9. doi: 10.1007/s11764-017-0641-0. [Epub ahead of print]
Impactfactor: 3,051

van der Vlugt M, Grobbee EJ, Bossuyt PM, **Bos AC**, Bongers E, Spijker W, Kuipers EJ, Lansdorp-Vogelaar I, Spaander MC, Dekker E. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing. *Gastroenterology*. 2017 May 5. pii: S0016-5085(17)35558-0. doi: 10.1053/j.gastro.2017.05.004. [Epub ahead of print]
Impactfactor: 18,392

van Waart H, Stuiver MM, van Harten WH, Geleijn E, de Maaker-Berkhof M, Schrama J, Geenen MM, Meerum Terwogt JM, van den Heiligenberg SM, [Hellendoorn-van Vreeswijk JA](#), Sonke GS, Aaronson NK. Recruitment to and pilot results of the PACES randomized trial of physical exercise during adjuvant chemotherapy for colon cancer. *Int J Colorectal Dis.* 2018 Jan;33(1):29-40. doi: 10.1007/s00384-017-2921-6. Epub 2017 Nov 9.
Impactfactor: 2,426

Verweij NM, Bonhof CS, Schiphorst AH, Maas HA, [Mols F](#), Pronk A, Hamaker ME. Quality of life in elderly patients with an ostomy - a study from the population-based PROFILES registry. *Colorectal Dis.* 2017 Dec 15. doi: 10.1111/codi.13989. [Epub ahead of print]
Impactfactor: 2,689

[Vissers PA](#), Martucci RB, Mols F, Bours MJL, Winkels RM, Kampman E, Weijenberg MP, [van de Poll-Franse LV](#), [Beijer S](#). The Impact of Body Mass Index and Waist Circumference on Health-related Quality of Life Among Colorectal Cancer Survivors: Results from the PROFILES Registry. *Nutr Cancer.* 2017 Oct 16:1-8. doi: 10.1080/01635581.2017.1367938. [Epub ahead of print]
Impactfactor: 2,447

Voorneveld PW, Reimers MS, Bastiaannet E, Jacobs RJ, van Eijk R, [Zanders MM](#), Herings RM, van Herk-Sukel MP, Kodach LL, van Wezel T, Kuppen PJ, Morreau H, van de Velde CJ, Hardwick JC, Liefers GJ. Statin Use After Diagnosis of Colon Cancer and Patient Survival. *Gastroenterology.* 2017 Aug;153(2):470-479.e4. doi: 10.1053/j.gastro.2017.05.011. Epub 2017 May 13.
Impactfactor: 18,392

Winkels RM, van Zutphen M, Kampman E, van Baar H, [Beijer S](#). Explaining the Obesity Paradox-Letter. *Cancer Epidemiol Biomarkers Prev.* 2017 Oct;26(10):1575. doi: 10.1158/1055-9965.EPI-17-0566. No abstract available.
Impactfactor: 4,142

4.2 Overige publicaties

Scheer R, Baidoshvili A, Zoidze S, [Elferink MA](#), Berkel AEM, Klaase JM, van Diest PJ. Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study. *World J Gastrointest Oncol.* 2017 Dec 15;9(12):466-474. doi: 10.4251/wjgo.v9.i12.466.

4.3 Posters

[Vink GR](#), Coebergh van den Braak RR, Punt CJ, Verkooijen HM, de Noo ME, Meijer GA, Koopman M. The Prospective Dutch ColoRectal Cancer cohort: a prospective nation-wide observational cohort study. ECCO, European Cancer Congress; 27-30 januari 2017; Amsterdam.

[Vink GR](#), Coebergh van den Braak RR, Bloemendal H, Coupé VM, [Elferink MA](#), Erdkamp FL, van Grevenstein WM, de Groot JW, Ijzermans JN, Intven MP, Los M, de Noo ME, van Oijen MG, Punt CJ, Rietbroek RC, Roeloffzen WW, Schiphorst AH, Schipper H, Stockmann HB, Tjin-A-Ton ML, van der Velden AM, Verhaar MJ, Vles WJ, Zimmermann DD, Meijer GA, Koopman M. The Prospective Dutch ColoRectal Cancer cohort (PLCRC): a prospective nationwide observational cohort study providing the infrastructure for registry based trials. AACR Annual Meeting, American Association for Cancer Research; 1-5 april 2017; Washington, D.C.

4.4 Presentaties en abstracts

Brouwer NP, Stijns RC, [Lemmens VE](#), Nagtegaal I, Beets-Tan RG, Fatterer J, [Verhoeven RH](#), de Wit JH. Clinical lymph node staging by imaging in colorectal cancer: a flip of the coin? ASCO Annual Meeting, American Society of Clinical Oncology; 206 juni 2017; Chicago.

Brouwer NP, [Bos AC](#), [Lemmens VE](#), Tanis P, Hugen N, Nagtegaal I, de Wilt H, [Verhoeven RH](#). 25 years of improving survival in colorectal cancer due to evolving treatment and care: results from the Netherlands Cancer Registry. European Society of Coloproctology scientific and annual meeting; 20-22 september 2017; Berlijn.

Kuiper JG, van Herk-Sukel MP, **Lemmens VE**, van Wijngaarden R, Herings RM. Insight into the role of the general practitioner in the management of colorectal cancer: record linkage of the Netherlands Cancer Registry and the general practitioner database of the pharmo database network. ISPOR annual European Congress, the International Society for Pharmacoeconomics and Outcomes Research; 4-8 november 2017; Glasgow.

Kuiper JG, van Herk-Sukel MP, **Lemmens VE**, Herings RM. Use of antipsychotics and the risk of colorectal cancer: a case-control study using data from the linked Netherlands Cancer Registry and pharmo database network population. ISPOR annual European Congress, the International Society for Pharmacoeconomics and Outcomes Research; 4-8 november 2017; Glasgow.

Rombouts A, Hugén N, **Elferink MA**, Poortmans P, Nagtegaal I, de Wilt H. Pathologic response after short versus long course (chemo) radiation therapy in rectal cancer patients. SSO annual cancer symposium, The society of surgical oncology; 15-18 maart 2017; Seattle.

Vink GR, van den Braak RC, Bloemendal H, Coupé V, **Elferink MA**, Erdkamp F, van Grevenstein H, de Groot JW, IJzermans J, Intven M, Los M, de Noo M, **van Oijen MG**, Punt C, Rietbroek R, Roeloffzen W, Schiphorst A, Schipper H, Stockmann H, Tjin-A-ton M, van der Velden A, Verhaar M, Vles W, Zimmerman D, Meijer G, Koopman M. The Prospective Dutch ColoRectal Cancer Cohort (PLCRC): a prospective nationwide observational study providing the infrastructure for registry based trials. AACR Annual Meeting, American Association for Cancer Research; 1-5 april 2017; Washington, D.C.

4.5 Proefschriften en promoties

Mol L. Quality aspects of Dutch colorectal cancer trials. Nijmegen: Radboud Universiteit; 6 juli 2017. Promotor: CJ Punt. Copromotoren: M Koopman, PO Ottevanger. Manuscriptcommissie: JH de Wit, RP Hermens **VE Lemmens**.

Razenberg LG. Systemic Treatment for advanced colorectal cancer: bridging the gap between clinical studies and daily practice. Rotterdam: Erasmus Universiteit; 21 april 2017. Promotor: **VE Lemmens**. Overige leden: **LV van de Poil-Franse**, S Sleijfer, C Verhoef.

5 Gynaecologische tumoren

5.1 Publicaties met impactfactor

de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileskin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, **Verhoeven-Adema KW**, Putter H, Creutzberg CL, Smit VTHBM; PORTEC study group. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. *Ann Oncol*. 2017 Nov 27. doi: 10.1093/annonc/mdx753. [Epub ahead of print] Impactfactor: 11,855

de Rooij BH, Ezendam NP, Nicolaije KA, Caroline Vos M, Pijnenborg JM, Boll D, Boss EA, Hermans RH, Engelhart KC, Haartsen JE, Pijlman BM, van Loon-Baelemans IE, Mertens HJ, Nolting WE, van Beek JJ, Roukema JA, Kruitwagen RF, **van de Poll-Franse LV**. Effects of Survivorship Care Plans on patient reported outcomes in ovarian cancer during 2-year follow-up - The ROGY care trial. *Gynecol Oncol*. 2017 Mar 7. pii: S0090-8258(17)30162-2. doi: 10.1016/j.ygyno.2017.02.041. [Epub ahead of print] Impactfactor: 4,959

Eggink FA, Mom CH, Boll D, **Ezendam NP**, Kruitwagen RFPM, Pijnenborg JMA, **van der Aa MA**, Nijman HW. Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients. *Gynecol Oncol*. 2017 May 25. pii: S0090-8258(17)30881-8. doi: 10.1016/j.ygyno.2017.05.025. [Epub ahead of print] Impactfactor: 4,959

Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, **Ezendam NP**, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, **van der Aa MA**. Corrigendum to "Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification" [*Eur J Cancer* 78 (2017) 82-90]. *Eur J Cancer*. 2017 Aug 22. pii: S0959-8049(17)31186-3. doi: 10.1016/j.ejca.2017.08.003. [Epub ahead of print] Impactfactor: 6,029

Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, **Ezendam NP**, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, **van der Aa MA**. Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification. *Eur J Cancer*. 2017 Apr 14;78:82-90. doi: 10.1016/j.ejca.2017.03.010. [Epub ahead of print] Impactfactor: 6,029

Houben E, van Haalen HG, Sparreboom W, Overbeek JA, **Ezendam NP**, Pijnenborg JM, Severens JL, van Herk-Sukel MP. Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes. *Med Oncol*. 2017 Apr;34(4):50. doi: 10.1007/s12032-017-0901-x. Impactfactor: 2,634

Jeppesen MM, **Ezendam NP**, Pijnenborg JM, Caroline Vos M, Boll D, Kruitwagen RF, Jensen PT, **van de Poll-Franse LV**. The impact of the survivorship care plan on health care use: 2-year follow-up results of the ROGY care trial. *J Cancer Surviv*. 2017 Sep 5. doi: 10.1007/s11764-017-0639-7. [Epub ahead of print] Impactfactor: 3,051

Leeson SC, Beaver K, **Ezendam NP**, Maćuks R, Martin-Hirsch PL, Miles T, Jeppesen MM, Jensen PT, Zola P. The future for follow-up of gynaecological cancer in Europe. Summary of available data and overview of ongoing trials. *Eur J Obstet Gynecol Reprod Biol*. 2017 Jan 19;210:376-380. doi: 10.1016/j.ejogrb.2017.01.025. [Epub ahead of print] Review. Impactfactor: 1,666

Matz M, Coleman MP, Sant M, Chirlaque MD, **Visser O**, Gore M, Allemani C; CONCORD Working Group (**Siesling S**). Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [*Gynecol. Oncol.* 144 (2017) 405-413]. *Gynecol Oncol*. 2017 Jul 5. pii: S0090-8258(17)30973-3. doi: 10.1016/j.ygyno.2017.06.032. [Epub ahead of print]

Impactfactor: 4,959

Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C; CONCORD Working Group (Siesling S, Visser O) et al. Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404]. Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30974-5. doi: 10.1016/j.ygyno.2017.06.033. [Epub ahead of print] No abstract available.

Impactfactor: 4,959

Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C; CONCORD Working Group (Siesling S, Visser O) et al. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017 Feb;144(2):396-404. doi: 10.1016/j.ygyno.2016.11.019.

Impactfactor: 4,959

Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KK, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N; AOCs study group., Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KB, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejertsen B, Ekici AB, Ellis S, Elvira M; EMBRACE Study., Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A; GEMO Study Collaborators., Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TV, Harrington PA, Harris HR, Hauke J; HEBON Study., Hein A, Henderson A, Hildebrandt MA, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FB, Holland H, Hoening MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T, Imyanitov EN, Isaacs C, Iversen ES, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen UB, John EM, Johnatty S, Jones ME, Kannisto P, Karlan BY, Karnezis A, Kast K; KConFab Investigators., Kennedy CJ, Khusnutdinova E, Kiemeny LA, Kiiski JI, Kim SW, Kjaer SK, Köbel M, Kopperud RK, Kruse TA, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larrañaga N, Larson MC, Lazaro C, Le ND, Le Marchand L, Lee JW, Lele SB, Leminen A, Leroux D, Lester J, Lesueur F, Levine DA, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu KH, Lubinński J, Luccarini C, Lundvall L, Mai PL, Mendoza-Fandiño G, Manoukian S, Massuger LF, May T, Mazoyer S, McAlpine JN, McGuire V, McLaughlin JR, McNeish I, Meijers-Heijboer H, Meindl A, Menon U, Mensenkamp AR, Merritt MA, Milne RL, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Odunsi K, Olah E, Olopade OI, Olsson H, Olswold C, O'Malley DM, Ong KR, Onland-Moret NC; OPAL study group., Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon TW, Paul J, Pearce CL, Pedersen IS, Peeters PH, Peissel B, Peixoto A, Pejovic T, Pelttari LM, Permut JB, Peterlongo P, Pezzani L, Pfeiler G, Phillips KA, Piedmonte M, Pike MC, Piskorz AM, Poblete SR, Pocza T, Poole EM, Poppe B, Porteous ME, Prier F, Prokofyeva D, Pugh E, Pujana MA, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez GC, Rodríguez-Antona C, Romm J, Rookus MA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Salvesen HB, Sandler DP, Schoemaker MJ, Senter L, Setiawan VW, Severi G, Sharma P, Shelford T, Siddiqui N, Side LE, Sieh W, Singer CF, Sobol H, Song H, Southey MC, Spurdle AB, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell LE, Sukiennicki G, Sutphen R, Sutter C, Swerdlow AJ, Szabo CI, Szafron L, Tan YY, Taylor JA, Tea MK, Teixeira MR, Teo SH, Terry KL, Thompson PJ, Thomsen LC, Thull DL, Tihomirova L, Tinker AV, Tischkowitz M, Tognazzo S, Toland AE, Tone A, Trabert B, Travis RC, Trichopoulou A, Tung N, Tworoger SS, van Altena AM, Van Den Berg D, van der Hout AH, van der Luit RB, Van Heetvelde M, Van Nieuwenhuysen E, van Rensburg EJ, Vanderstichele A, Varon-Mateeva R, Vega A, Edwards DV, Vergote I, Vierkant RA, Vijai J, Vratimos A, Walker L, Walsh C, Wand D, Wang-Gohrke S, Wappenschmidt B,

Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, Whittemore AS, Wijnen JT, Wilkens LR, Wolk A, Woo M, Wu X, Wu AH, Yang H, Yannoukakos D, Ziogas A, Zorn KK, Narod SA, Easton DF, Amos CI, Schildkraut JM, Ramus SJ, Ottini L, Goodman MT, Park SK, Kelemen LE, Risch HA, Thomassen M, Offit K, Simard J, Schmutzler RK, Hazelett D, Monteiro AN, Couch FJ, Berchuck A, Chenevix-Trench G, Goode EL, Sellers TA, Gayther SA, Antoniou AC, Pharoah PD. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet.* 2017 Mar 27. doi: 10.1038/ng.3826. [Epub ahead of print]

Impactfactor: 27,959

Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA; RARECARENet Working Group ([Visser O](#)). Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. *Eur J Surg Oncol.* 2017 Nov 3. pii: S0748-7983(17)30947-2. doi: 10.1016/j.ejso.2017.09.025. [Epub ahead of print]

Impactfactor: 3,522

[Timmermans M](#), [Schuurman MS](#), [Ho VK](#), Massuger LF, Nijman HW, van Gorp T, Sonke GS, Kruitwagen RF, [van der Aa MA](#). Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. *Gynecol Oncol.* 2017 Nov 9. pii: S0090-8258(17)31505-6. doi: 10.1016/j.ygyno.2017.11.009. [Epub ahead of print]

Impactfactor: 4,959

[Timmermans M](#), Sonke GS, Van de Vijver KK, [van der Aa MA](#), Kruitwagen RF. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. *Eur J Cancer.* 2017 Nov 24;88:31-37. doi: 10.1016/j.ejca.2017.10.030. [Epub ahead of print]

Impactfactor: 6,029

[van Broekhoven ME](#), [de Rooij BH](#), Pijnenborg JM, Vos MC, Boll D, Kruitwagen RF, [van de Poll-Franse LV](#), [Ezendam NP](#). Illness perceptions and changes in lifestyle following a gynecological cancer diagnosis: A longitudinal analysis. *Gynecol Oncol.* 2017 Mar 6. pii: S0090-8258(17)30157-9. doi: 10.1016/j.ygyno.2017.02.037. [Epub ahead of print]

Impactfactor: 4,959

van der Linden M, [Schuurman MS](#), Bulten J, [van der Aa MA](#), Massuger L, de Hullu J. Incidence and survival of glandular vulvar malignancies in the Netherlands. *Gynecol Oncol.* 2017 Jan 24. pii: S0090-8258(17)30064-1. doi: 10.1016/j.ygyno.2017.01.020. [Epub ahead of print]

Impactfactor: 4,959

Vermeulen CK, Tadesse W, [Timmermans M](#), Kruitwagen RF, Walsh T. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer. *Eur J Obstet Gynecol Reprod Biol.* 2017 Oct 19;219:100-105. doi: 10.1016/j.ejogrb.2017.10.019. [Epub ahead of print]

Impactfactor: 1,666

5.2 Posters

[Timmermans M](#), [van der Aa MA](#), van de Vijver KK, Kruitwagen RF, Sonke GS. Interval between cytoreductive surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. ESGO international meeting, the European Society of Gynaecological oncology; 4-7 november 2017; Wenen.

5.3 Presentaties en abstracts

[de Rooij BH](#), Ikiz H, Boll D, Pijnenborg H, Pijlman B, Kruitwagen RF, [van de Poll-Franse LV](#), Vos MC, [Ezendam NP](#). Recurrent cancer is associated with dissatisfaction with care: a longitudinal analysis in ovarian and endometrial cancer patients. ESGO international meeting, the European Society of Gynaecological oncology; 4-7 november 2017; Wenen.

[de Rooij BH](#), [Ezendam NP](#), [Nicolaije KA](#), Vos MC, Pijnenborg JM, Boll D, Kruitwagen RF, [van de Poll-Franse LV](#). The indirect effects of survivorship care plans on quality of life, anxiety and depression: the

rogy care trial. MASCC/ISOO annual meeting, Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology; 22-24 juni 2017; Washington.

Ezendam NP, Rietveld M, Vos C, **van de Poll-Franse LV**, Ottevanger N, Husson O. Gastro-intestinal symptoms in ovarian cancer patients during survivorship: a cross-sectional study from the profiles registry. MASCC/ISOO annual meeting, Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology; 22-24 juni 2017; Washington.

Schuurman MS, **Timmermans M**, van de Vijver K, van Gorp T, Kruitwagen RF, **van der Aa MA**, **Lemmens VE**. Borderline ovarian tumors: a nationwide overview of incidence, survival and risk of subsequent invasive ovarian tumors. ESGO international meeting, the European Society of Gynaecological oncology; 4-7 november 2017; Wenen.

Timmermans M, **van der Aa MA**, van de Vijver KK, Kruitwagen RF, Sonke GS. Interval between cytoreductive surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. ESGO international meeting, the European Society of Gynaecological oncology; 4-7 november 2017; Wenen.

Timmermans M. No improvement in long term survival for epithelial ovarian cancer patients: a population based study between 1989 and 2014 in the Netherlands. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

6 Hemato-oncologie

6.1 Publicaties met impactfactor

Arts LP, van de Poll-Franse LV, van den Berg SW, Prins JB, Husson O, **Mols F**, Brands-Nijenhuis AVM, Tick L, **Oerlemans S**. Lymphoma InterVENTion (LIVE) - patient-reported outcome feedback and a web-based self-management intervention for patients with lymphoma: study protocol for a randomised controlled trial. *Trials*. 2017 Apr 28;18(1):199. doi: 10.1186/s13063-017-1943-2. Impactfactor: 1,969

Beijers AJ, **Oerlemans S, Mols F**, Eurelings M, Minnema MC, Vreugdenhil A, **van de Poll-Franse LV**. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. *Ann Hematol*. 2017 Jan 23. doi: 10.1007/s00277-017-2927-8. [Epub ahead of print] Impactfactor: 3,083

Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, Carreira H, Spika D, Marcos-Gragera R, Peris-Bonet R, Piñeros M, Sant M, Kuehni CE, Murphy MFG, Coleman MP, Allemani C; CONCORD Working Group (**Siesling S, Visser O**). Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. *Lancet Haematol*. 2017 May;4(5):e202-e217. doi: 10.1016/S2352-3026(17)30052-2. Epub 2017 Apr 11. Impactfactor: 7,123

Dinmohamed AG, Visser O, Posthuma EF, **Huijgens PC**, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M. MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands. *Cancer Epidemiol*. 2017 Sep 11;50(Pt A):137-140. doi: 10.1016/j.canep.2017.08.016. [Epub ahead of print] Impactfactor: 2,343

Geelen IG, Thielen N, Janssen JJ, Hoogendoorn M, Roosma TJ, Willemsen SP, Valk PJ, **Visser O**, Cornelissen JJ, Westerweel PE. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival. *Haematologica*. 2017 Aug 31. pii: haematol.2017.175265. doi: 10.3324/haematol.2017.175265. [Epub ahead of print] No abstract available. Impactfactor: 7,702

Geelen IG, Thielen N, Janssen JJ, Levin MD, Hoogendoorn M, **Visser O**, Cornelissen JJ, Westerweel PE. Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival. *Eur J Haematol*. 2017 Jul 18. doi: 10.1111/ejh.12928. [Epub ahead of print] No abstract available. Impactfactor: 2,653

Geelen IG, Thielen N, Janssen JJ, Hoogendoorn M, Roosma TJA, Valk PJ, **Visser O**, Cornelissen JJ, Westerweel PE. Omitting cytogenetic assessment from routine treatment response monitoring in CML is safe. *Eur J Haematol*. 2017 Dec 29. doi: 10.1111/ejh.13023. [Epub ahead of print] Impactfactor: 2,653

Geelen IG, Thielen N, Janssen JJ, Hoogendoorn M, Roosma TJ, Willemsen SP, **Visser O**, Cornelissen JJ, Westerweel PE. Treatment outcome in a population-based 'real-world' cohort of chronic myeloid leukemia patients. *Haematologica*. 2017 Aug 31. pii: haematol.2017.174953. doi: 10.3324/haematol.2017.174953. [Epub ahead of print] Impactfactor: 7,702

Husson O, Prins JB, Kaal SE, **Oerlemans S**, Stevens WB, Zebrack B, van der Graaf WT, **van de Poll-Franse LV**. Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. *Acta Oncol*. 2017 Jan 12:1-7. doi: 10.1080/0284186X.2016.1267404. [Epub ahead of print] Impactfactor: 3,156

Oerlemans S, Arts LP, Horevoorts NJ, van de Poll-Franse LV. "Am I normal?" The Wishes of Patients With Lymphoma to Compare Their Patient-Reported Outcomes With Those of Their Peers. *J Med Internet Res.* 2017 Aug 15;19(8):e288. doi: 10.2196/jmir.7079. Impactfactor: 5,175

Thong MS, Kicinski M, Coens C, Giusti F, **van de Poll-Franse LV**, Bogaerts J, Liu L. A population-based approach to compare patient-reported outcomes of long-term Hodgkin's lymphoma survivors according to trial participation: a joint study from the Patient-Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship registry and European Organisation for Research and Treatment of Cancer. *Eur J Cancer Prev.* 2017 Jun 1. doi: 10.1097/CEJ.0000000000000381. [Epub ahead of print] Impactfactor: 2,556

van Beurden-Tan CH, Franken MG, **Blommestein HM, Uyl-de Groot CA**, Sonneveld P. Reply to X. Armoiry et al. *J Clin Oncol.* 2017 Jul 12;JCO2017737569. doi: 10.1200/JCO.2017.73.7569. [Epub ahead of print] No abstract available. Impactfactor: 24,008

van Beurden-Tan CH, Franken MG, **Blommestein HM, Uyl-de Groot CA**, Sonneveld P. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. *J Clin Oncol.* 2017 Feb 27;JCO2016711663. doi: 10.1200/JCO.2016.71.1663. [Epub ahead of print] Impactfactor: 24,008

van de Poll-Franse LV, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S, Daniëls L, Creutzberg CL, Cocks K, Malak S, Caocci G, Molica S, Chie W, Efficace F; EORTC Quality of Life Group. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. *Qual Life Res.* 2017 Nov 10. doi: 10.1007/s11136-017-1718-y. [Epub ahead of print] Impactfactor: 2,344

van der Meulen M, **Dinmohamed AG, Visser O**, Doorduijn JK, Bromberg JEC. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015. *Leukemia.* 2017 Apr 28. doi: 10.1038/leu.2017.128. [Epub ahead of print] No abstract available. Impactfactor: 11,702

van Eggermond AM, **Schaapveld M**, Janus CP, de Boer JP, Krol AD, Zijlstra JM, van der Maazen RW, Kremer LC, van Leerdam ME, **Louwman MW, Visser O**, De Bruin ML, Aleman BM, van Leeuwen FE. Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. *Br J Cancer.* 2017 Jun 20. doi: 10.1038/bjc.2017.177. [Epub ahead of print] Impactfactor: 6,176

van Nimwegen FA, Ntentas G, Darby SC, **Schaapveld M**, Hauptmann M, Lugtenburg PJ, Janus CP, Daniels L, van Leeuwen FE, Cutter DJ, Aleman BM. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. *Blood.* 2017 Jan 31. pii: blood-2016-09-740332. doi: 10.1182/blood-2016-09-740332. [Epub ahead of print] Impactfactor: 13,164

6.2 Overige publicaties

Dinmohamed AG, Issa DE, van der Poel MW, Schouten HC, Lugtenburg PJ, Chamuleau ME, Zweegmans S, **Visser O**. Treatment and relative survival in very elderly patients with DLBCL in the Netherlands. *Blood advances* 2017 Sept 21;1:1839-1841.

6.3 Posters

Brink M, Visser O, Minnema MC, Zweegman S, Sonneveld P, **Dinmohamed AG**. When performance of cytogenetics matters: a population-based study in the Netherlands on newly diagnosed multiple myeloma patients. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

6.4 Presentaties en abstracts

Brink M, Visser O, Minnema MC, Zweegman S, Sonneveld P, **Dinmohamed AG**. When performance of cytogenetics matters: a population-based study in the Netherlands on newly diagnosed multiple myeloma patients. EHA congress, European Hematology Association; 22-25 juni 2017; Madrid.

Dinmohamed AG, van der Meulen M, **Visser O**, Doorduijn L, Bromberg J. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015. EHA congress, European Hematology Association; 22-25 juni 2017; Madrid.

Dinmohamed AG, Visser O, Posthuma W, Raymakers R, Doorduijn J. Relative survival reaches a plateau in hairy cell leukemia: a population-based study on incidence, primary treatment and survival among 1,427 patients diagnosed in the Netherlands, 1989-2014. EHA congress, European Hematology Association; 22-25 juni 2017; Madrid.

Geelen I, Thielen N, Janssen J, Hoogendoorn M, **Visser O**, Cornelissen J, Westerweel P. Validation of the eutos long term survival score in Dutch CML-patients. EHA congress, European Hematology Association; 22-25 juni 2017; Madrid.

Lugtenburg PJ, **Visser O**, Doorduijn JK, **Dinmohamed AG**. Treatment and survival of primary effusion lymphoma (PEL): a population-based study among 25 patients diagnosed in the Netherlands between 2002 and 2015. International Conference on malignant lymphoma; 14-17 juni 2017; Lugano.

Wester R, **Dinmohamed AG**, Sonneveld P, Broijl A, Blijlevens N. Pomalidomide with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a prospective analysis in a population-based registry. EHA congress, European Hematology Association; 22-25 juni 2017; Madrid.

7 Hoofdhalskanker

7.1 Publicaties met impactfactor

Dal Maso L, Tavilla A, Pacini F, Serraino D, [van Dijk BA](#), Chirlaque MD, Capocaccia R, Larrañaga N, Colonna M, Agius D, Ardanaz E, Rubió-Casadevall J, Kowalska A, Virdone S, Mallone S, Amash H, De Angelis R; EUROCARE-5 Working Group. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. *Eur J Cancer*. 2017 Apr 11;77:140-152. doi: 10.1016/j.ejca.2017.02.023. [Epub ahead of print]
Impactfactor: 6,029

de Ridder M, Balm AJ, Baatenburg de Jong RJ, Terhaard CH, Takes RP, Slingerland M, Dik E, Sedee RJ, de Visscher JG, Bouman H, Willems SM, Wouters MW, Smeele LE, [van Dijk BA](#); Dutch Head and Neck Research Group. Variation in head and neck cancer care in the Netherlands: A retrospective cohort evaluation of incidence, treatment and outcome. *Eur J Surg Oncol*. 2017 Mar 8. pii: S0748-7983(17)30364-5. doi: 10.1016/j.ejso. 2017.02.017. [Epub ahead of print]
Impactfactor: 3,522

Fles R, [Bos AC](#), Supriyati, Rachmawati D, Waliyanti E, Tan IB, Haryana SM, Schmidt MK, Dewi FST. The role of Indonesian patients' health behaviors in delaying the diagnosis of nasopharyngeal carcinoma. *BMC Public Health*. 2017 May 25;17(1):510. doi: 10.1186/s12889-017-4429-y.
Impactfactor: 2,265

Halmos GB, Bras L, [Siesling S](#), van der Laan BF, Langendijk JA, [van Dijk BA](#). Age-specific incidence and treatment patterns of head and neck cancer in the Netherlands-A cohort study. *Clin Otolaryngol*. 2017 Sep 26. doi: 10.1111/coa.12991. [Epub ahead of print]
Impactfactor: 2,523

Petersen JF, Timmermans AJ, [van Dijk BA](#), Overbeek LI, Smit LA, Hilgers FJ, Stuiver MM, van den Brekel MW. Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands. *Eur Arch Otorhinolaryngol*. 2017 Oct 28. doi: 10.1007/s00405-017-4766-6. [Epub ahead of print]
Impactfactor: 1,660

Valstar MH, de Ridder M, van den Broek EC, Stuiver MM, [van Dijk BA](#), van Velthuysen ML, Balm AJ, Smeele LE. Salivary gland pleomorphic adenoma in the Netherlands: A nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence. *Oral Oncol*. 2017 Mar;66:93-99. doi: 10.1016/j.oraloncology.2017.01.004.
Impactfactor: 4,794

van Overveld LF, Takes RP, Vijn TW, Braspenning JC, de Boer JP, Brouns JJ, Bun RJ, [van Dijk BA](#), Dortmans JAF, Dronkers EA, van Es RJ, Hoebers FJ, Kropveld A, Langendijk JA, Langeveld TP, Oosting SF, Verschuur HP, de Visscher JG, van Weert S, Merckx MA, Smeele LE, Hermens RP. Feedback preferences of patients, professionals and health insurers in integrated head and neck cancer care. *Health Expect*. 2017 Jun 15. doi: 10.1111/hex.12567. [Epub ahead of print]
Impactfactor: 1,669

8 Huidkanker

8.1 Publicaties met impactfactor

Ascott A, Langan SM, García-Doval I, Descalzo MA, Schmidt SAJ, Nijsten T, **Hollestein LM**. Report from the first European Dermato-Epidemiology Network forum. *Br J Dermatol*. 2017 Oct;177(4):e168-e171. doi: 10.1111/bjd.15874. Epub 2017 Sep 17.
Impactfactor: 4,706

Eggen CA, Durgaram VV, van Doorn R, Mooi WJ, Pardo LM, Pasmans SG, **Hollestein LM**. Incidence and relative survival of melanoma in children and adolescents in the Netherlands, 1989-2013. *J Eur Acad Dermatol Venereol*. 2017 Oct 28. doi: 10.1111/jdv.14665. [Epub ahead of print]
Impactfactor: 3,528

Hollestein L, Weinstock M, Le Roux E, Olsen C. More Than Many: How to Manage the Most Frequent Cancer? *J Invest Dermatol*. 2017 Sep;137(9):1823-1826. doi: 10.1016/j.jid.2017.06.017. Review.
Impactfactor: 6,287

Nissen LH, Pierik M, Derikx LA, de Jong E, Kievit W, van den Heuvel TR, van Rosendael AR, Plasmeijer EI, Dewint P, **Verhoeven RH**, Overbeek LI, Nagtegaal ID, Hoentjen F, van der Meulen-de Jong AE. Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma. *Inflamm Bowel Dis*. 2017 Aug 22. doi: 10.1097/MIB.0000000000001191. [Epub ahead of print]
Impactfactor: 4,525

Oude Ophuis CM, **Louwman MW**, Grünhagen DJ, Verhoef C, van Akkooi AC. Implementation of the 7th Edition AJCC Staging System: Effects on Staging and Survival for pT1 Melanoma. A Dutch Population Based Study. *Int J Cancer*. 2017 Jan 20. doi: 10.1002/ijc.30607. [Epub ahead of print]
Impactfactor: 6,513

van der Leest RJ, **Hollestein LM**, Liu L, Nijsten T, de Vries E. Risks of different skin tumour combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population-based cohorts: 1989-2009. *J Eur Acad Dermatol Venereol*. 2017 Sep 12. doi: 10.1111/jdv.14587. [Epub ahead of print]
Impactfactor: 3,528

Verstijnen J, Damude S, Hoekstra HJ, Kruijff S, Ten Tije AJ, **Louwman MW**, Bastiaannet E, Stuiver MM. Practice variation in Sentinel Lymph Node Biopsy for melanoma patients in different geographical regions in the Netherlands. *Surg Oncol*. 2017 Dec;26(4):431-437. doi: 10.1016/j.suronc.2017.08.006. Epub 2017 Sep 1.
Impactfactor: 3,304

Verver D, **Louwman MW**, Koljenović S, Verhoef C, Grünhagen DJ, van Akkooi AC. Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria: A Dutch population-based study. *Eur J Cancer*. 2017 Dec 4. pii: S0959-8049(17)31371-0. doi: 10.1016/j.ejca.2017.10.031. [Epub ahead of print]
Impactfactor: 6,029

Waalboer-Spuij R, **Hollestein LM**, Timman R, **van de Poll-Franse LV**, Nijsten TE. Development and Validation of the Basal and Squamous Cell Carcinoma Quality of Life Questionnaire. *Acta Derm Venereol*. 2017 Sep 27. doi: 10.2340/00015555-2806. [Epub ahead of print]
Impactfactor: 3,653

Waalboer-Spuij R, **Hollestein LM**, **van de Poll-Franse LV**, Nijsten TE. Histological diagnosis of basal cell carcinoma is not associated with life expectancy in elderly Dutch people; a population-based cohort study. *Br J Dermatol*. 2017 Jan 23. doi: 10.1111/bjd.15310. [Epub ahead of print]
Impactfactor: 4,706

8.2 Overige publicaties

Greveling K, Wakkee M, Nijsten T, van den Bos RR, [Hollestein LM](#). Epidemiologie van lentigo maligna en lentigo maligna melanoom, 1989-2013. Ned Tijds voor Dermatologie en Venereologie. 2017 Feb 2;27:88-90.

Zoutendijk J, van der Leest RJ, Nijsten T, Mooi WJ, van der Rhee JI, de Vries E, [Hollestein LM](#). Stijgende incidentie van dunne melanomen in Nederland. Ned Tijdschr Geneeskd. 2017 24 juni;161(25):D1030.

8.3 Presentaties en abstracts

Franken M, Leeneman B, Jochems A, Schouwenberg M, [Aarts MJ](#), van Akkooi A, van den Berkmortel F, van den Eertwegh A, de Groot J, van der Hoeven J, Hospers G, Kapiteijn E, Koornstra R, Kruit W, [Louwman MW](#), Piersma D, van Rijn R, Suijkerbuijk K, ten Tije A, Vreugdenhil G, Wouters M, van Zeijl M, Haanen J, Uyl-de Groot C. Healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in Dutch clinical practice. ISPOR annual European Congress, the International Society for Pharmacoeconomics and Outcomes Research; 4-8 november 2017; Glasgow.

9 Longkanker

9.1 Publicaties met impactfactor

Brinkhof S, Groen HJ, **Siesling S**, IJzerman MJ. Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences. PLoS One. 2017 Dec 7;12(12):e0189251. doi: 10.1371/journal.pone.0189251. eCollection 2017.

Impactfactor: 2,806

Dahele M, **Damhuis RA**. Relationship Between Tumor Location and Outcome in Patients With Early-Stage Lung Cancer. Clin Lung Cancer. 2017 Apr 23. pii: S1525-7304(17)30110-9. doi: 10.1016/j.clc.2017.04.005. [Epub ahead of print] No abstract available.

Impactfactor: 3,434

Dahele M, **Damhuis RA**. The Relationship between Histology, Stage, and Type of Treatment in Patients with Early-Stage Lung Cancer. J Thorac Oncol. 2017 May;12(5):e58-e59. doi: 10.1016/j.jtho.2017.01.024. No abstract available.

Impactfactor: 6,595

Damhuis RA, Widder J, Senan S. Population-based Results of Chemoradiotherapy for Limited Stage Small Cell Lung Cancer in The Netherlands. Clin Oncol (R Coll Radiol). 2017 Oct 25. pii: S0936-6555(17)30442-9. doi: 10.1016/j.clon.2017.10.008. [Epub ahead of print]

Impactfactor: 3,236

Damhuis RA, Senan S, Belderbos JS. Usage of Prophylactic Cranial Irradiation in Elderly Patients With Small-cell Lung Cancer. Clin Lung Cancer. 2017 Nov 21. pii: S1525-7304(17)30317-0. doi: 10.1016/j.clc.2017.11.005. [Epub ahead of print]

Impactfactor: 3,434

Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, **Damhuis RA**, van den Broek EC, Speel EM, Dingemans AC; PALGA group. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J. 2017 Jun 1;49(6). pii: 1601838. doi: 10.1183/13993003.01838-2016. Print 2017 Jun.

Impactfactor: 10,569

Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJ, Smit EF, **Damhuis RA**, van den Broek EC, Chabrier A, Foll M, McKay JD, Fernandez-Cuesta L, Speel EM, Dingemans AC. Molecular subtypes of pulmonary large cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2017 Oct 24. pii: clincanres.1921.2017. doi: 10.1158/1078-0432.CCR-17-1921. [Epub ahead of print]

Impactfactor: 9,619

Derks JL, van Suylen RJ, Thunnissen E, den Bakker M, Groen H, Smit E, **Damhuis RA**, van den Broek E, Speel EJ, Dingemans AC. Why we should improve current practice of diagnosing and treating pulmonary large cell neuroendocrine carcinomas in patients with advanced disease. Eur Respir J. 2017 Oct 26;50(4). pii: 1701658. doi: 10.1183/13993003.01658-2017. Print 2017 Oct. No abstract available.

Impactfactor: 10,569

Dickhoff C, Dahele M, Smit EF, Paul MA, Senan S, Hartemink KJ, **Damhuis RA**. Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry. Lung Cancer 2017 110 (14-18)

Impactfactor: 4,294

Driessen EJ, Schulkes KJ, Dingemans AC, van Loon JG, Hamaker ME, **Aarts MJ**, Janssen-Heijnen ML. Patterns of treatment and survival among older patients with stage III non-small cell lung cancer. Lung cancer 2017 December.

Impactfactor: 4,294

Driessen EJ, **Aarts MJ**, Bootsma GP, van Loon JG, Janssen-Heijnen ML. Trends in treatment and relative survival among non-small cell lung cancer patients in the Netherlands (1990-2014): disparities between younger and older patients. *Lung cancer* 2017 June;108:198-204.
Impactfactor: 4,294

Slotman BJ, Faivre-Finn C, van Tinteren H, **Keijser A**, Praag J, Kneijens J, Hatton M, van Dam I, van der Leest A, Reymen B, Stigt J, Haslett K, Tripathi D, Smit EF, Senan S. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the Phase III CREST trial. *Lung Cancer* 2017 108:150-153.
Impactfactor: 4,294

Walraven I, **Damhuis RA**, Ten Berge MG, Roskamp M, van Eycken L, de Ruyscher D, Belderbos JS. Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium. *Clin Oncol (R Coll Radiol)*. 2017 Nov;29(11):e177-e185. doi: 10.1016/j.clon.2017.07.012. Epub 2017 Aug 2.
Impactfactor: 3,236

Weberpals J, Jansen L, Haefeli WE, Hoffmeister M, Wolkewitz M, Herk-Sukel MPPV, **Vissers PA**, Brenner H. Pre- and post-diagnostic β -blocker use and lung cancer survival: A population-based cohort study. *Sci Rep*. 2017 Jun 6;7(1):2911. doi: 10.1038/s41598-017-02913-8.
Impactfactor: 4,259

9.2 Posters

Douma G, **Fransen HP**, Venmans BJ, **Aarts MJ**. End of life treatment of metastatic lung cancer in the Netherlands: a population based study. ERS congress, European Respiratory Society; 9-13 september 2017; Milaan.

Douma G, **Fransen HP**, Venmans BJ, **Aarts MJ**. End of life treatment of metastatic lung cancer in the Netherlands: a population based study. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

9.3 Presentaties en abstracts

Blaauwgeers H, **Damhuis RA**, Witte B, de Langen J, Thunnissen E. Adjuvant treatment and survival in TNM-7 pT3N0M0 non-small cell lung cancer in the Netherlands: a support for including histology to staging. European Congress of Pathology; 2-6 september 2017; Amsterdam.

Kuijpers C, Hendriks L, Derks J, Dingemans AM, van den Heuvel M, **Damhuis RA**, Willems S. Correlation of molecular status and anatomic sites of metastases (mets) at diagnosis (Dx) of non-small cell lung cancer (NSCLC). ELCC conference, European Lung Cancer; 5-8 mei 2017; Genève.

10 Neuro-endocriene tumoren

10.1 Publicaties met impactfactor

Madani A, Thomassen I, van Gestel YR, van der Bilt JD, Haak HR, de Hingh IH, **Lemmens VE**. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis. *Ann Surg Oncol*. 2017 Feb 15. doi: 10.1245/s10434-016-5734-x. [Epub ahead of print]
Impactfactor: 4,041

11 Neuro-oncologie

11.1 Publicaties met impactfactor

Gatta G, Peris-Bonet R, [Visser O](#), Stiller C, Marcos-Gragera R, Sánchez MJ, Lacour B, Kaatsch P, Berrino F, Rutkowski S, Botta L; EUROCARE-5 Working Group. [Geographical variability in survival of European children with central nervous system tumours](#). Eur J Cancer. 2017 Jul 6;82:137-148. doi: 10.1016/j.ejca.2017.05.028. [Epub ahead of print]
Impactfactor: 6,029

12 Upper GI & HPB

12.1 Publicaties met impactfactor

Bakens MJ, Lemmens VE, de Hingh IH. Socio-economic status influences the likelihood of undergoing surgical treatment for pancreatic cancer in the Netherlands. *HPB (Oxford)*. 2017 Feb 17. pii: S1365-182X(17)30040-0. doi: 10.1016/j.hpb.2017.01.010. [Epub ahead of print]
Impactfactor: 3,290

Beck N, Busweiler LA, Schouwenburg MG, Fiocco M, Cats A, Voncken FE, Wijnhoven BP, van Berge Henegouwen MI, Wouters MW, van Sandick JW; Dutch Upper GI Cancer Audit (DUCA) (**Lemmens VE**) Group and the Dutch Gastric Cancer Perioperative Therapy Study group. Factors contributing to variation in the use of multimodality treatment in patients with gastric cancer: A Dutch population based study. *Eur J Surg Oncol*. 2018 Feb;44(2):260-267. doi: 10.1016/j.ejso.2017.11.023. Epub 2017 Dec 13.
Impactfactor: 3,522

Brenkman HJ, Visser E, van Rossum PS, **Siesling S**, van Hillegersberg R, Ruurda JP. Association Between Waiting Time from Diagnosis to Treatment and Survival in Patients with Curable Gastric Cancer: A Population-Based Study in the Netherlands. *Ann Surg Oncol*. 2017 Mar 28. doi: 10.1245/s10434-017-5820-8. [Epub ahead of print]
Impactfactor: 4,041

Brenkman HJ, Ruurda JP, **Verhoeven RH**, van Hillegersberg R. Safety and feasibility of minimally invasive gastrectomy during the early introduction in the Netherlands: short-term oncological outcomes comparable to open gastrectomy. *Gastric Cancer*. 2017 Feb 9. doi: 10.1007/s10120-017-0695-8. [Epub ahead of print]
Impactfactor: 5,454

Busweiler LA, Henneman D, Dikken JL, Fiocco M, van Berge Henegouwen MI, Wijnhoven BP, van Hillegersberg R, Rosman C, Wouters MW, van Sandick JW; Dutch Upper GI Cancer Audit group (**Lemmens VE**). Failure-to-rescue in patients undergoing surgery for esophageal or gastric cancer. *Eur J Surg Oncol*. 2017 Oct;43(10):1962-1969. doi: 10.1016/j.ejso.2017.07.005. Epub 2017 Jul 29.
Impactfactor: 3,522

Busweiler LA, Schouwenburg MG, van Berge Henegouwen MI, Kolfschoten NE, de Jong PC, Rozema T, Wijnhoven BP, van Hillegersberg R, Wouters MW, van Sandick JW; Dutch Upper Gastrointestinal Cancer Audit (DUCA) group (**Lemmens VE**). Textbook outcome as a composite measure in oesophagogastric cancer surgery. *Br J Surg*. 2017 Feb 27. doi: 10.1002/bjs.10486. [Epub ahead of print]
Impactfactor: 5,899

Busweiler LA, Dikken JL, Henneman D, van Berge Henegouwen MI, **Ho VK**, Tollenaar RAEM, Wouters MWJM, van Sandick JW. The influence of a composite hospital volume on outcomes for gastric cancer surgery: A Dutch population-based study. *J Surg Oncol*. 2017 May 15. doi: 10.1002/jso.24562. [Epub ahead of print]
Impactfactor: 2,993

Coebergh van den Braak RR, van Rijssen LB, van Kleef JJ, **Vink GR**, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch OR, Coene PP, Coupé VM, Dekker JW, van Eijck CH, **Elferink MA**, Erdkamp FL, van Grevenstein WM, de Groot JW, van Grieken NC, de Hingh IH, Hulshof MC, Ijzermans JN, Kwakkenbos L, **Lemmens VE**, Los M, Meijer GA, Molenaar IQ, Nieuwenhuijzen GA, de Noo ME, **van de Poll-Franse LV**, Punt CJ, Rietbroek RC, Roeloffzen WW, Rozema T, Ruurda JP, van Sandick JW, Schiphorst AH, Schipper H, Siersema PD, Slingerland M, Sommeijer DW, Spaander MC, Sprangers MA, Stockmann HB, Strijker M, van Tienhoven G, Timmermans LM, Tjin-A-Ton ML, van der Velden AM, Verhaar MJ, Verkooijen HM, Vles WJ, de Vos-Geelen JM, Wilmink JW, Zimmerman DD, **van Oijen MG**, Koopman M, Besselink MG, van Laarhoven HW; Dutch Pancreatic Cancer Group, Dutch Upper GI Cancer Group and PLCRC working group. Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. *Acta Oncol*. 2017 Jul 19:1-8. doi: 10.1080/0284186X.2017.1346381. [Epub ahead of print]
Impactfactor: 3,156

de Jong RG, Burden AM, de Kort S, van Herk-Sukel MPP, **Vissers PA**, Janssen PKC, Haak HR, Masclee AAM, de Vries F, Janssen-Heijnen MLG. Impact of detection bias on the risk of gastrointestinal cancer and

its subsites in type 2 diabetes mellitus. *Eur J Cancer*. 2017 Apr 29;79:61-71. doi: 10.1016/j.ejca.2017.03.039. [Epub ahead of print]
Impactfactor: 6,029

de Jong RG, Burden AM, de Kort S, van Herk-Sukel M, **Vissers PA**, Janssen PK, Haak HR, Masclee AA, de Vries F, Janssen-Heijnen ML. No decreased risk of gastrointestinal cancers in users of metformin in The Netherlands; a time-varying analysis of metformin exposure. *Cancer Prev Res (Phila)*. 2017 Mar 8. pii: canprevres.0277.2016. doi: 10.1158/1940-6207.CAPR-16-0277. [Epub ahead of print]
Impactfactor: 3,985

Frouws MA, Mulder BG, Bastiaannet E, **Zanders MM**, van Herk-Sukel MP, de Leede EM, Bonsing BA, Mieog JS, Van de Velde CJ, Liefers GJ. No association between metformin use and survival in patients with pancreatic cancer: An observational cohort study. *Medicine (Baltimore)*. 2017 Mar;96(10):e6229. doi: 10.1097/MD.00000000000006229.
Impactfactor: 1,804

Haj Mohammad N, **Bernards N, van Putten M, Lemmens VE**, van Oijen MGH, van Laarhoven HWM. Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer. *Eur J Cancer*. 2017 Apr 13;78:28-36. doi: 10.1016/j.ejca.2017.03.008. [Epub ahead of print]
Impactfactor: 6,029

Henneman D, Dikken JL, Putter H, **Lemmens VE, van der Geest LG**, van Hillegersberg R, Verheij M, van de Velde CJ, Wouters MW. In Reply: Centralization of Upper Gastrointestinal Cancer Care Should Be Dictated by Quality of Care. *Ann Surg Oncol*. 2017 Nov 13. doi: 10.1245/s10434-017-6222-7. [Epub ahead of print] No abstract available.
Impactfactor: 4,041

Ho VK, Jansen EP, Wijnhoven BP, Neelis KJ, van Sandick JW, **Verhoeven RH, Lemmens VE**, van Laarhoven HW. Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer. *Ann Surg Oncol*. 2017 Aug 22. doi: 10.1245/s10434-017-6048-3. [Epub ahead of print]
Impactfactor: 4,041

Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, **van der Geest LG, Lemmens VE**, Van Eycken L, De Schutter H, Johannesen TB, Frstrup CW, Mortensen MB, Primic-Žakelj M, Zadnik V, Becker N, Hackert T, Mägi M, Cassetti T, Sassatelli R, Grützmann R, Merkel S, Gonçalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Sant M, Minicozzi P, Mazzaferro V, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Büchler MW, Schrotz-King P, Brenner H. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. *Gut*. 2017 Nov 20. pii: gutjnl-2017-314828. doi: 10.1136/gutjnl-2017-314828. [Epub ahead of print]
Impactfactor: 16,658

Lykoudis PM, Partelli S, Muffatti F, Caplin M, Falconi M, Fusai GK; RARECARENet Working Group (**Visser O**). Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. *Eur J Surg Oncol*. 2017 Oct 16. pii: S0748-7983(17)30941-1. doi: 10.1016/j.ejso.2017.08.019. [Epub ahead of print]
Impactfactor: 3,522

Nelen SD, **van Putten M, Lemmens VE**, Bosscha K, de Wilt JH, **Verhoeven RH**. Effect of age on rates of palliative surgery and chemotherapy use in patients with locally advanced or metastatic gastric cancer. *Br J Surg*. 2017 Aug 9. doi: 10.1002/bjs.10621. [Epub ahead of print]
Impactfactor: 5,899

Nelen SD, Heuthorst L, **Verhoeven RH**, Polat F, Kruyt PM, Reijnders K, Ferenschild FT, Bonenkamp JJ, Rutter JE, de Wilt JH, Spillenaar Bilgen EJ. Impact of Centralizing Gastric Cancer Surgery on Treatment, Morbidity, and Mortality. *J Gastrointest Surg*. 2017 Aug 16. doi: 10.1007/s11605-017-3531-x. [Epub ahead of print]
Impactfactor: 2,963

Nelen SD, **Verhoeven RH, Lemmens VE**, de Wilt JH, Bosscha K. Increasing survival gap between young and elderly gastric cancer patients. *Gastric Cancer*. 2017 Mar 9. doi: 10.1007/s10120-017-0708-7. [Epub ahead of print]

Impactfactor: 5,454

van der Geest LG, Lemmens VE, de Hingh IH, van Laarhoven CJ, Bollen TL, Nio CY, van Eijck CH, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group. *Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer*. Br J Surg. 2017 Aug 22. doi: 10.1002/bjs.10602. [Epub ahead of print]
Impactfactor: 5,899

van der Geest LG, Haj Mohammad N, Besselink MG, **Lemmens VE**, Portielje JE, van Laarhoven HW, Wilmink JH; Dutch Pancreatic Cancer Group. *Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer*. Cancer Med. 2017 Oct 16. doi: 10.1002/cam4.1240. [Epub ahead of print]
Impactfactor: 3,362

Visser E, Brenkman HJ, **Verhoeven RH**, Ruurda JP, van Hillegersberg R. *Weekday of gastrectomy for cancer in relation to mortality and oncological outcomes - A Dutch population-based cohort study*. Eur J Surg Oncol. 2017 Jul 29. pii: S0748-7983(17)30591-7. doi: 10.1016/j.ejso.2017.07.007. [Epub ahead of print]
Impactfactor: 3,522

12.2 Posters

van der Geest LG, Haj Mohammad N, Besselink M, **Lemmens VE**, Portielje J, van Laarhoven H, Wilmink H. *Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer*. ECCO, European Cancer Congress; 27-30 januari 2017; Amsterdam.

van Putten M, de Vos-Geelen J, Nieuwenhuijzen GA, Siersema PD, **Lemmens VE**, Rosman C, van der Sangen MJ, **Verhoeven RH**. *Long-term survival improvement in oesophageal cancer in the Netherlands*. ESMO, World Congress on Gastrointestinal Cancer; 28 juni -1 juli 2017; Barcelona.

van Putten M, Lemmens VE, van Laarhoven HW, Pruijt HF, Nieuwenhuijzen GA, **Verhoeven RH**. *Poor compliance with peri-operative treatment in patients with resectable gastric cancer*. ESMO, World Congress on Gastrointestinal Cancer; 28 juni -1 juli 2017; Barcelona.

12.3 Presentaties en abstracts

Vink GR. *Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative*. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

Zijlstra M. *Choosing no treatment at all-in pancreatic cancer: results of a population-based registry*. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

12.4 Proefschriften en promoties

Bernards N. *Hard to digest?: treatment and survival of patients with metastatic upper gastrointestinal cancer*. Rotterdam: Erasmus Universiteit; 13 april 2017. Promotor: **VE Lemmens**.

13 Urogenitale kanker

13.1 Publicaties met impactfactor

Bouman-Wammes EW, van den Berg HP, **de Munck L**, Beeker A, Smorenburg CH, Vervenne WL, Coenen JL, Verheul HM, Gerritsen WR, Van den Eertwegh AJ. A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. *Eur J Cancer*. 2017 Dec 18;90:1-9. doi: 10.1016/j.ejca.2017.11.021. [Epub ahead of print]
Impactfactor: 6,029

Cuypers M, Lamers RE, Kil PJ, The R, Karssen K, **van de Poll-Franse LV**, de Vries M. A global, incremental development method for a web-based prostate cancer treatment decision aid and usability testing in a Dutch clinical setting. *Health Informatics J*. 2017 Jul 1:1460458217720393. doi: 10.1177/1460458217720393. [Epub ahead of print]
Impactfactor: 3,021

Cuypers M, Lamers RE, Cornel EB, **van de Poll-Franse LV**, de Vries M, Kil PJ. The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset. *Support Care Cancer*. 2017 Nov 10. doi: 10.1007/s00520-017-3953-8. [Epub ahead of print]
Impactfactor: 2,698

Lamers RE, Cuypers M, de Vries M, **van de Poll-Franse LV**, Ruud Bosch JL, Kil PJ. How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer. *Urol Oncol*. 2017 Feb;35(2):37.e9-37.e17. doi: 10.1016/j.urolonc.2016.09.007. Epub 2016 Oct 27.
Impactfactor: 3,668

Poorthuis MH, **Vernooij RW**, van Moorselaar RJ, de Reijke TM. Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials. *Seminars in Oncology* 2017 Oct 10. doi.org/10.1053/j.seminoncol.2017.10.005.
Impactfactor: 6,212

van Leeuwen M, Kieffer JM, Efficace F, Fossà SD, Bolla M, Collette L, Colombel M, De Giorgi U, Holzner B, **van de Poll-Franse LV**, van Poppel H, White J, de Wit R, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group.; Genito-Urinary Cancers Group and Radiation Oncology Group.; and the NCRN Testis Clinical Studies Group. International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. *Health Qual Life Outcomes*. 2017 May 11;15(1):97. doi: 10.1186/s12955-017-0670-4.
Impactfactor: 2,143

13.2 Overige publicaties

Hermans TJ, Fransen van de Putte EE, Horenblas S, **Lemmens VE**, **Aben KK**, van der Heijden MS, Beerepoot LV, **Verhoeven RH**, van Rhijn BW. Perioperatieve behandelingen en radicale cystectomie voor blaaskanker: een trendanalyse over 10.338 patiënten in Nederland. *Tijdschr Urologie* 2017 Juli; 7(4):87-100.

13.3 Posters

Jansen H, van Oort I, van Andel G, Wijsman BP, Pos F, Hulshof MC, Hulsbergen-van de Kaa CA, van Leenders GJ, Fütterer JJ, Somford DM, Busstra MB, van Moorselaar RJ, Kiemeny LA, **Aben KK**. Immediate treatment versus active-surveillance in low-risk prostate cancer: the role of hospital-related factors. *WEON congres, Epidemiological Methods for Implementation Research*; 8-9 juni; Antwerpen.

van Ras HW, **Jansen H, Aben KK**. Active surveillance for patients with intermediate-risk prostate cancer in the Netherlands: a population-based study. WEON congres, Epidemiological Methods for Implementation Research; 8-9 juni; Antwerpen.

Vernooij RW, Horenblas S, Smilde TJ, Kiemeneij LA, Koldewijn EL, de Wit R, **Verhoeven RH**. Risk classification of metastatic germ cell tumours in the Netherlands according to the IGCCC: a nationwide population-based study. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

13.4 Presentaties en abstracts

Boer H, Lubberts S, Bunschoek S, Nuver J, Lefrandt JD, Steursma G, Sluiter WJ, **Siesling S**, Berendsen AJ, Gietema JA. Safety and utility of shared survivorship care after chemotherapy for testicular cancer. ASCO Annual Meeting, American Society of Clinical Oncology; 2-6 juni 2017; Chicago.

Bouman-Wammes EW, **de Munck L**, van den Berg HP, Beeker A, Smorenburg CH, Verheul HM, Gerritsen WR, van den Eertwegh AJ. A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in castration resistant prostate cancer patients who have progressed after response to prior docetaxel chemotherapy: the Recardo trial. ASCO Annual Meeting, American Society of Clinical Oncology; 2-6 juni 2017; Chicago.

de Reijke T, **Vernooij RW**, van Oort I, **Aben KK**. Elderly prostate cancer patients have a worse prognosis than younger patients: a population-based study in the Netherlands. AAEU annual meeting, Association of Academic European Urologists; 14-17 december 2017; Dresden.

Tähtinen RM, Cartwright R, **Vernooij RW**, Hunskar S, Rørtveit G, Guyatt GH, Tikkinen KA. Mode of vaginal delivery and urinary leakage: population-based prospective cohort study. ICS congress, International Continence Society; 12-15 september 2017; Florence.

Vernooij RW, van Oort I, de Reijke T, **Aben KK**. Elderly prostate cancer patients have a worse prognosis than younger patients: a population-based study in the Netherlands. AUA meeting, American Urological Association; 12-16 mei 2017; Boston.

Vernooij RW, van Oort I, de Reijke T, **Aben KK**. Elderly prostate cancer patients have a worse prognosis than younger patients: a population-based study in the Netherlands. EAU congres, European Association of Urology; 24-28 maart 2017; Londen.

Vernooij RW, van Oort I, de Reijke T, **Aben KK**. Elderly prostate cancer patients have a worse prognosis than younger patients: a population-based study in the Netherlands. IACR conference, International Association of Cancer Registries; 17-19 oktober; Utrecht.

B1 Impactfactoren tijdschriften

Van de 197 peer-reviewed publicaties werd 98 % gepubliceerd in een tijdschrift met een impactfactor. De maximale impactfactor bedroeg 40,137 en de gemiddelde impactfactor was 6,3. (de impactfactor is gebaseerd op 2017 Journal Citation Reports®).

Tabel 1 Overzicht tijdschriften met impactfactor

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Acta Dermato-Venereologica	3,653	1
Acta Oncologica	3,156	4
Annals of Hematology	3,083	1
Annals of Oncology	11,855	3
Annals of Surgical Oncology	4,041	7
BJC British Journal of Cancer	6,176	2
BJD British Journal of Dermatology	4,706	2
BJS British Journal of Surgery	5,899	3
Blood	13,164	1
BMC Cancer	3,288	2
BMC Public Health	2,265	1
BMJ Open	2,369	3
Breast Cancer Research	6,345	1
Breast Cancer Research and Treatment	3,626	13
Cancer Epidemiology	2,343	1
Cancer Epidemiology, Biomarkers & Prevention	4,142	1
Cancer Medicine	3,362	1
Cancer Prevention Research	3,985	1
Clinical Breast Cancer	2,816	1
Clinical Cancer Research	9,619	1
Clinical Colorectal Cancer	4,507	2
Clinical Lung Cancer	3,434	2
Clinical Nutrition	4,548	1
Clinical Oncology	3,236	2
Clinical Otolaryngology	2,523	1
Colorectal Disease	2,689	1
Diabetes & Metabolism	4,101	1
EJSO European Journal of Surgical Oncology	3,522	8
European Archives of Oto-Rhino-Laryngology	1,660	1
European Journal of Cancer	6,029	22
European Journal of Cancer Prevention	2,556	1
European Journal of Epidemiology	7,226	1
European Journal of Haematology	2,653	2
European Journal of Obstetrics & Gynecology and Reproduc. Biol.	1,666	2
European Respiratory Journal	10,569	2
Evidence-Based Complementary and Alternative Medicine	1,740	1
Gastric cancer	5,454	2
Gastroenterology	18,392	2
Gut	16,658	2

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Gynecologic Oncology	4,959	8
Haematologica	7,702	2
Health and Quality of Life Outcomes	2,143	1
Health Expectations	1,669	1
Health Informatics Journal	3,021	1
HPB Journal Oxford	3,290	1
IJC International Journal of Cancer	6,513	4
Implementation Science	3,354	1
Inflammatory Bowel Diseases	4,525	1
International Journal of Clinical Oncology	2,064	1
International Journal of Colorectal Disease	2,426	1
International Journal of Dermatology	1,560	1
International Journal of Radiation Oncology, Biology, Physics	5,133	1
JAMA Oncology	16,559	2
JMIR Cancer	5,175	1
JNCI Journal of the National Cancer Institute	12,589	1
Journal of Cancer Survivorship	3,051	2
Journal of Clinical Oncology	24,008	4
Journal of Gastrointestinal Surgery	2,963	1
Journal of Investigative Dermatology	6,287	1
Journal of Medical Internet Research	5,175	1
Journal of Psychosomatic Research	2,809	1
Journal of Surgical Oncology	2,993	1
Journal of the European Academy of Dermatology and Venereology	3,528	3
Journal of Thoracic Oncology (JTO)	6,595	1
Leukemia	11,702	1
Lung Cancer	4,294	4
Medical Oncology	2,634	1
Medicine (Baltimore)	1,804	1
Nature	40,137	1
Nature Genetics	27,959	2
Nutrition and Cancer	2,447	1
Oncology Nursing Forum	1,763	1
Oral oncology	4,794	1
Pharmacogenomics	2,350	1
PloS One	2,806	3
Quality of Life Research	2,344	2
Scientific Reports	4,259	2
Seminars in Oncology	6,212	1
Supportive Care in Cancer	2,698	3
Surgical oncology	3,304	1
The BMJ	20,785	1
The Breast	2,801	3
The European Journal of Health Economics	2,500	1
The Lancet Haematology	7,123	1
The Lancet Oncology	33,900	3
Trials	1,969	2

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Urologic Oncology	3,668	1
Value in Health	4,235	1

Tabel 2 Overzicht tijdschriften zonder impactfactor

<i>Naam tijdschrift:</i>	<i>Aantal publicaties:</i>
Blood advances	1
Huisarts en wetenschap	1
International Journal of Palliative Nursing	1
Nederlands Tijdschrift voor Dermatologie en Venereologie	1
Nederlands Tijdschrift voor Urologie	1
NtvG Nederlands Tijdschrift voor Geneeskunde	3
World Journal of Gastrointestinal Oncology	1

Integraal Kankercentrum
Nederland
info@iknl.nl
www.iknl.nl

